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Abstract
The papain-like cysteine protease family (C1 proteases) is highly important because of its
involvement in research and industrial applications and its role in various human diseases.
Protein inhibitors are an important aspect of C1 protease biology and are relevant to its clin-
ical, industrial and research importance. To study the interaction between the proteases and
the inhibitors it is very useful to have accurate structural models of the protease-inhibitor
complexes. To this end, a high-throughput pipeline for modelling complexes of papain-
like cysteine proteases and protein inhibitors was implemented and tested (Tastan Bishop
& Kroon, 2011). The pipeline utilizes a novel technique for obtaining modelling templates
by using superpositioning to combine coordinates from separate experimental structures. To
test the pipeline, models of complexes with known structures (test set) were modelled using
many different templates and the resultant models evaluated to compare the quality of the
different templates. It was found that use of the new technique to obtain templates did not
introduce significant errors, while allowing closer homologs to be used for modelling - lead-
ing to more accurate models. The test set models were also used to evaluate certain steps
of the modelling protocol. The effect of Rosetta energy minimization on model accuracy
and the use of Rosetta energy and DOPE Z-score values to identify accurate models were
investigated. Several complexes were then modelled using the best available templates ac-
cording to criteria informed by the previous results. A website was built that allows a user to
download any of the metrics or models produced in the study. This website is accessible at
http://rubi.ru.ac.za/cpmdb.
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Chapter 1
Introduction
1.1 Chapter overview
The purpose of this chapter is to familiarize the reader with some of the information and con-
cepts relevant to the project. Because this project was originally inspired by work on cysteine
proteases from malaria parasites, and contains some further work on these enzymes, the chap-
ter starts off with a very brief discussion of malaria. It goes on by introducing the various
protein families involved in the project. The papain-like cysteine proteases are introduced
first, followed by the cystatins and the chagasin-like inhibitors. For each of these families, it
gives some information regarding the history, function, classification and importance of the
family. Computer based structure prediction is then discussed briefly. Homology modelling
and protein docking as structure prediction techniques are introduced and explained shortly.
Thereafter, the main sources of data used in the project are introduced and some information
about each is given. The chapter ends with a very brief summary.
1.2 Malaria
Malaria is a parasitic disease that causes fever and other flu-like symptoms. It is a lethal
disease, resulting in an estimated 767 000 deaths in 2008 (WHO, 2009). Young children
and pregnant women are especially vulnerable. There are two species responsible for almost
all cases of clinical malaria, they are Plasmodium falciparum and Plasmodium vivax. P.
falciparum is by far the more lethal of the two species but P. vivax can cause long term
infection with recurring symptoms (Price et al. , 2007). Drug resistance is a major problem
in the fight against malaria (Hayton & Su, 2004). There is currently an international program
for the eradication of malaria and a discontinuity in the ability to treat the disease effectively,
using drugs, would be a major setback (WHO, 2009). Thus, there is a strong need for novel
anti-malarial drugs. Cysteine proteases, in particular falcipain-2 of P. falciparum, have been
well characterized and are considered very promising drug targets. There are a number of
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potential falcipain-2 inhibitors currently under investigation as drugs for malaria (Ettari et al.
, 2010).
1.3 Papain-like cystein proteases
1.3.1 Summary
Papain-like cysteine proteases (C1 proteases) are a very important and well-studied enzyme
family. They catalyze the hydrolytic cleavage of peptide bonds. Their most common func-
tions are in digestion and protein turnover but there are several other, more specialized, func-
tions. They have been found to play roles in many parasitic processes and non-pathogenic
human diseases. Several human and parasite C1 proteases have been proposed as drug targets
and some inhibitors are currently in clinical trials. Protein inhibitors of C1 proteases are also
of interest in agricultural biotechnology.
1.3.2 History
The C1 protease family is one of the oldest known enzyme families. The first member of the
C1 family to be isolated and studied was papain, a cysteine protease that occurs naturally in
the latex of the papaya fruit (Carica papaya). The name papain derives from the name of the
fruit - papaya. In a 1885 paper which reported the isolation and analysis of papain it is also
mentioned that the leaves and juice of papaya fruit was used to tenderize meat in the countries
where it naturally occurred (Martin, 1885). In 1962, the three-dimensional (3D) structure of
papain was one of the earliest protein structures to be published (Drenth et al. , 1962). Since
the discovery of papain, a great many more C1 proteases, occurring in every living kingdom,
have been identified and studied.
1.3.3 Classification
The classification of proteases and their inhibitors described here is the classification schema
implemented by the MEROPS database (Rawlings et al. , 2010). A list of the clans and
families in the database can be viewed at the website http://merops.sanger.ac.uk
Cysteine proteases as a group are defined as enzymes that catalyze the hydrolytic cleavage
of peptide bonds, utilizing a catalytic cystein residue. They are divided into clans which are
further divided into families. Cysteine proteases are grouped together in a clan if they are
thought to share an evolutionary common ancestor. The different clans are thus thought to be
products of independent evolution. Clan-members are grouped together in a family if there is
detectable sequence similarity between them. The classification as a cysteine protease is thus
dependent on a specific function while the subdivision are dependent on evolutionary history.
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Figure 1.1 – The molecular structure of papain (PDB ID: 1STF) in cartoon representation. The
L-domain is on the left and the R-domain on the right. The residues of the catalytic triad are
shown in stick representation and their atoms are colored according to elements. The asparagine
is visible on top, cysteine in the left and histidine in the middle.
The clans are identified by a single capital alphabetic letter ie. A, B, C. This is appended to the
letter C (for Cysteine) to give a clan identifier eg. CA, CB and CC that uniquely identifies the
protease clan. As homology between different clans, previously thought unrelated, became
apparent, many of the clans were merged and thus the letters do not follow the alphabetic
order. Families are identified by a numeric number. The number is unique across all the clans
and not just within one clan. Thus, we only get one family C1, C2, etc. and not one in every
clan. It is therefore redundant to specify the clan when specifying the family.
The papain-like cysteine protease family has received the family identifier C1 and falls in
clan CA. It is the largest family of cysteine proteases and is almost universally distributed
throughout the living kingdoms (Rawlings & Barrett, 1994). Within the C1 family there
are 2 large sub-families namely the cathepsin-L like and cathepsin-B like subfamilies. The
differentiating characteristic between them is the presence of a short insert, about 20 amino
acids long, close to the active site in the cathepsin-B like subfamily. This insert forms a rather
flexible loop that can interact with the substrate and with inhibitors (Sajid & McKerrow, 2002;
Redzynia et al. , 2008). There are also other sub-families in the C1 family but they have been
left out of this project due to insufficient data.
1.3.4 Structure and function
The enzyme consists of 2 distinct domains named the L and R domains. The catalytic cys-
teine residue is part of an α-helix in the L domain. The active site of the enzyme is at the
interface of the 2 domains where a cleft is formed. The cleft contains binding pockets so that
a polypeptide can bind to the cleft in an elongated conformation with the side-chains of its
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amino acids accommodated in the binding pockets. This ensures the correct orientation of
the labile bond to the catalytic cysteine residue.
The catalytic mechanism of cysteine proteases is similar to that of serine proteases, involving
nucleophilic attack. The thiol group of cysteine is a better nucleophile than the hydroxyl
group of serine because of the extra electron shell on the sulphur atom. The thiol group’s
nucleophilic character is increased by a nearby histidine that acts as a base and accepts the
proton of the thiol group to yield a very nucleophilic thiolate group. The histidine then
carries an imidazolium group. The two groups are closely associated in space and together
form a charge relay diad. A conserved nearby asparagine residue serves as the oxyanion hole
(Vernet et al. , 1995). Cysteine proteases require a reducing environment to function and this
condition is usually met under cellular conditions by the presence of glutathione (Sajid &
McKerrow, 2002). The structure of papain is shown in Figure 1.1. Using papain numbering,
the catalytic residues are CYS 25, HIS 159 and ASN 175.
1.3.5 Biological roles
The human members of the family are known as the cathepsins and have important roles in
the immune system, the protein renewal process and resorption of bone and cartilage. An
important factor of their significance is that certain cathepsins are the only enzymes capable
of degrading key proteins of the extracellular matrix. Eleven cathepsins have been described
and are identified by letters of the alphabet. The letters B, C, F, H, K, L, O, S, V, W and X
have been assigned. The biological roles they play have been reviewed by Vasiljeva et al.
(2007).
C1 proteases of parasitic organisms play diverse and often important roles in parasite’s life-
cycles. The most common function is digestion. Roles in encystment, immune evasion,
cell invasion and others are also important. An extensive review was compiled by Sajid &
McKerrow (2002).
1.3.6 Regulation
Protein degradation is an activity that needs to be tightly controlled to prevent the harmful
degradation of the wrong proteins. This regulation is carried out using three main mecha-
nisms: synthesis as an inactive precursor, subcellular containment and inhibition by protein
inhibitors (Sajid & McKerrow, 2002; Turk et al. , 2002).
C1 proteases are synthesized with an N-terminal prodomain that blocks access to the active
site cleft. This prodomain has to be cleaved off for the enzyme to become active. The
prodomain is also required for the correct folding of the enzyme although some C1 members
from malaria parasites have been found to fold correctly in the absence of the prodomain.
The cleavage of the prodomain and subsequent activation of the enzyme is often triggered
by changes in pH. Sometimes the prodomain is cleaved of by other proteases when acting in
protease cascades.
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C1 proteases are usually localized to subcellular structures or excreted from the cell. The
most common subcellular structures are lysosomes and digestive vacuoles. This prevents the
indiscriminate degradation of useful proteins. Subcellularly-contained proteases are often
released upon cell damage or necrosis and this can cause problems for the organism.
C1 activity is also regulated by protein inhibitors. The cystatin superfamily of inhibitors is
the most common and most well studied family of protein inhibitor. Another, more recently
discovered, family is the chagasin-like inhibitors. More details about the inhibitors are given
in the sections dedicated to them (Section 1.4 and 1.5).
1.3.7 Clinical significance
Both human and non-human-derived C1 proteases play roles in disease and have been iden-
tified as promising drug targets. A lot of progress has been made in developing cysteine
protease inhibitors for use as drugs (McKerrow et al. , 2008).
C1 proteases from parasitic organisms are involved in many diseases. Functions include di-
gestion of proteins for nutrition, ex/en-cystment, cell/tissue invasion and immuno-modulation.
These proteases are also usually very immunogenic. C1 proteases have been identified as im-
portant in various parasites for example:
• Malaria - Digestion of host hemoglobin for nutrients, erythrocyte invasion and erythro-
cyte rupture (Rosenthal, 2004).
• Liver flukes - Tissue invasion, immuno modulation and digestion (Alcala-Canto et al. ,
2007; Dowd et al. , 1994; Dalton et al. , 2003).
• Amoebiasis - Tissue invasion (Freitas et al. , 2009; Tillack et al. , 2006; Moncada et al.
, 2003).
• Hookworm - Digestion of host hemoglobin for nutrients (Ranjit et al. , 2009; Williamson
et al. , 2004).
• Bilharzia - Digestion of host hemoglobin for nutrients (Caffrey et al. , 2002; Dvorák
et al. , 2009).
• Leishmaniasis - Unclear (Mahmoudzadeh-Niknam & McKerrow, 2004; Mottram et al.
, 2004).
• Chagas disease - Function unclear (Cazzulo et al. , 1997).
Human C1 proteases (cathepsins) are also involved in disease. A good review of the functions
and disease involvement of human C1 proteases is Vasiljeva et al. (2007). For example,
cathepsins can be involved in the following diseases:
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• Cancer - Cathepsin-B and cathepsin-L play a role in tissue invasion by degrading the
extracellular matrix, creating space for the tumor to grow. They are also involved in
regulating cell-proliferation and apoptosis.
• Immune system and viral infections - Cathepsins are involved in processing antigen to
be displayed on MHCII and also the process where the antigen fragment is loaded onto
the MHCII molecule. Some viruses only become active after cleavage by cathepsins.
• Osteoporosis - Cathepsin-K plays a major role in bone resorption and degradation of the
bone matrix. Cathepsin-L also plays a role as indicated by knock-out mice although the
form of the involvement is still unknown. Osteoporosis is an imbalance in the normal
bone resorption process, leading to weakened bones.
• Rheumatoid Arthritis - Cathepsin-B, -L and -K are thought to involved in the destruc-
tion of bone tissue in this auto-immune disease.
With such a wide array of diseases it is clear why there is a lot of research interest in C1
proteases. If a library of non-toxic inhibitors were available with known inhibition profiles
for all the cathepsins and important parasitic proteases the number of diseases that could be
treated is large.
1.3.8 Economical significance
The clinical importance of C1 proteases also imply an economical importance as diseases
cause loss of productivity and cost money to treat. In addition, C1 proteases have various
industrial and research applications of economical significance. For example papain is used
as meat-tenderizer (Ashie et al. , 2002). In many plants, C1 proteases act as a defense against
herbivorous insects and in turn the insects use C1 proteases to digest plant material (Shindo
& Van der Hoorn, 2008). This is important in agriculture. Papain is sometimes used in the
cosmetic industry as a skin or hair softener although it can lead to allergic reactions (Sim et al.
, 2000; Soto-Mera et al. , 2000). In biochemical research, papain is used for the cleavage of
antibodies into variable and non-variable fragments. This allows researchers to carry out
experiments that would not be possible otherwise. Medical applications of C1 proteases
include the treatment of dental caries (Lopes et al. , 2007). The use of papain in topical
treatments of chronic wounds is being discontinued due to side-effects, mainly allergies.
1.3.9 Cysteine proteases of malaria parasites
The falcipains are a group of 4 related cysteine proteases of the P. falciparum species. The
group is made up out of falcipain-1, falcipain-2, falcipain-2’ and falcipain-3. For an excellent
introduction to the falcipains, see Ettari et al. 2010. The sequencing of the P. falciparum
genome has greatly aided the identification and study of these enzymes. The falcipains have
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been extensively studied and characterized largely because they have been identified as drug
targets to treat malaria (Rosenthal, 2004).
Various studies have been carried out to determine the function of each of the falcipains. The
best characterized function is hemoglobin degradation by falcipain-2 and falcipain-3 (Shenai
et al. , 2000; Sijwali et al. , 2001). Treatment of malaria with cysteine protease inhibitors
prevents growth of cultures in vitro, and cures malaria in mouse models (Rosenthal et al. ,
1993). Another function under investigation is degradation of erythrocyte cytoskeletal pro-
teins (Hanspal et al. , 2002). This is necessary for erythrocyte rupture during the parasite
life-cycle. The main candidate for cytoskeletal degradation is falcipain-2, due to pH consid-
erations. Falcipain-1 does not appear to be essential to the organism, as strains, in which the
gene has been blocked, develops normally in vitro. However, falcipain-1 may play a role in
functions that are not required in vitro such as immuno-evasion or other interactions with the
host or vector. Falcipain-2’ was discovered last and is almost identical to falcipain-2, showing
over 90% sequence identity. There is a slight difference between the affinities of falcipain-2
and falcipain-2’ for certain cytoskeletal proteins (Jeong et al. , 2006).
The structure of falcipain-2 was experimentally determined using X-ray diffraction in 2006
(Wang et al. , 2006). This indicated two novel features not found in other cysteine proteases
of the papain family. The two features have been named the ”arm” and ”nose”. The nose is
thought to enable the protease to fold properly in the absence of the prodomain, a feat unique
to falcipain-2 and related Plasmodium cysteine proteases. Residues have been identified that
are important for the functioning of the ”nose” motif via mutagenic experiments. The ”arm”
motif is thought to bind to hemoglobin. Deletion of the ”arm” feature leads to loss of function
against hemoglobin, while activity against artificial peptide substrates are unaffected.
The vivapains are a group of cysteine proteases in P. vivax. The vivapains are orthologs of
the falcipains and share significant sequence similarity. A lot of what is known about the
vivapains are related to studies of the falcipains, as P. vivax cannot be readily cultured like P.
falciparum. At least one biochemical characterization of vivapain-2 and vivapain-3 has been
carried out (Na et al. , 2004b). This showed slight inconsistencies with the characteristics
of the falcipains, but both of the enzymes are able to degrade native hemoglobin as well as
cytoskeletal proteins. Thus, while the specifics may not be exactly like that of the falcipains,
vivapain-2 and 3 are thought to be involved in the same broad processes as falcipain-2 and
3. The vivapains are also potential drug targets and some hope that a general inhibitor may
be designed to inhibit both the falcipains and the vivapains. An analysis of the variation in
vivapain sequences within different P. vivax populations have been carried out and support
their potential as drug targets (Na et al. , 2004a).
1.3.10 Available data
As a result of the importance of the C1 family, and the long time it’s been under study, there
is a large amount of data available for these enzymes. There are well over 2500 sequences
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available in Pfam (Finn et al. , 2010) and more than 250 experimentally determined structures
are available in the PDB (Berman et al. , 2000).
1.4 Cystatins
1.4.1 Summary
Cystatins are protein inhibitors of cysteine proteases. They bind to the protease active site
and physically block the substrate from binding. The side-chains of the inhibitor binds in
the binding pockets of the protease but the backbone of the inhibitor turns away from the
active site where cleavage would normally occur (Figure 1.2). They are used to prevent
uncontrolled degradation of valuable proteins by endogenous cysteine proteases and also, in
some cases, to inhibit the cysteine proteases of other species in inter-species interactions.
Since the interaction between the inhibitor and the protease is non-covalent and the inhibitor
binds to the active site, the inhibition is classified as competitive, reversible inhibition.
1.4.2 History
The first cystatin to be described was ovocystatin, isolated from chicken (Gallus gallus) egg
white although at the time it wasn’t called cystatin (Fossum & Whitaker, 1968). Later, similar
inhibitors were discovered in mammalian tissue. The name, cystatin, was proposed in the
eighties (Barrett, 1981). The structure of a ovocystatin was the first structure of a cystatin
molecule to be published in 1988 (Bode et al. , 1988). Thereafter several more structures
were published including the structures of human-derived cystatins.
1.4.3 Classification
The classification schema described here is that followed by the MEROPS database (Rawl-
ings et al. , 2010). The process for classifying the inhibitors was described in an earlier paper
(Rawlings et al. , 2004). Protease inhibitors are classified into clans and families based on
homology. Homology is inferred based on structural or sequence similarity. Inhibitors with
similar tertiary structure are grouped together in a clan. The clan is then further divided into
families based on sequence homology. Clans are named with the the letter ”I” or ”J” (”I” for
inhibitor) followed by another letter. The reason for using ”J” is because there are more than
26 clans and thus to be able to name them all another letter apart from ”I” was needed. ”J”
was chosen because it is the first letter in the alphabet after ”I”. Families are indicated with
an ”I” followed by a number. As with proteases the number is unique to that family across all
clans. Some proteins contain more then one cystatin domain. In some cases these domains
are not from the same cystatin sub-family. As such, the classification of cystatins applies to
the inhibitory domains and not to the whole protein.
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Cystatins were given the identifier I25 and, together with the latexin family, they form clan
IH.
Cystatins are classified into four subfamilies. The subfamilies are based on sequence similar-
ity but also share many functional characteristics. Each sub-family has a single ”type” protein
which serves as the model for the sub-family. If a cystatin domain shows sequence similarity
to that protein above a certain threshold it is classified in that sub-family. The subfamilies are
listed below with accompanying ”type protein”:
I25A Cystatin-A (Homo sapiens) - Type I These are mostly endocytoplasmic cystatins but
can also be found in body fluids. They typically do not posses disulphide bonds and
are not glycosylated. Human cystatin-A and cystatin-B fall into this sub-family. This
sub-family is also known as the stefins.
I25B Ovocystatin (Gallus gallus) - Type II These are mostly excreted cystatins and contain
two conserved disulphide bonds and are sometimes glycosylated. Human cystatin-C
and kininogen subunits-2 and -3 fall into this sub-family. In some literature this sub-
family is referred to as the cystatin sub-family, usually when referring to the sub-family
I25A as stefins.
I25C Metallopeptidase inhibitor (snake venom, Bothrops jararaca) These are not inhibitors
of C1 proteases. Human kininogen subunit-1 falls in this sub-family.
I25D Unassigned There are some members of the cystatin family that could not be assigned
to one of the other sub-families and they have been put here for the time being.
For simplicity, the names ”Type I” and ”Type II” will be used in the rest of the study for the
families indicated above.
1.4.4 Structure and function
See Figure 1.2 for a visual representation of cystatin interacting with a protease. Cystatins
contain a four-strand β-sheet with an α-helix lying across it, perpendicular to the direction
of the strands. Cystatin binds to a C1 protease via three distinct binding regions. These
regions are made up of the N-terminal and two loops between the strands of the β-sheet. The
inhibitory function is achieved by binding to the protease active site and physically blocking
access to it. The backbone turns away from the protease in the place where a substrate
protein would normally be cleaved. As such there is no labile bond in the position where
cleavage would normally take place. Cystatins are reversible, competitive inhibitors since
the interaction is temporary and competes with the substrate for access to the binding site.
Although the interaction is reversible, it is a tight-binding inhibitor with inhibition constants,
typically, in the nanomolar range.
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Figure 1.2 – The molecular structure of cystatin-B (PDB ID: 1STF) shown in cartoon representa-
tion. The protease (papain) is shown in surface representation in blue with the catalytic cysteine
in purple. From the N-terminal, the backbone of the inhibitor fits in the active site cleft but
turns away from the protease at the catalytic cysteine, rejoining the cleft on the other side of the
catalytic residue.
1.4.5 Biological roles
Cystatins play a crucial role in preventing proteolysis by C1 proteases; therefore their biolog-
ical role often corresponds with that of the proteases they inhibit. Type I cystatins are often
used intracellularly to prevent proteolysis by proteases that accidentally leak from their sub-
cellular compartments (Turk et al. , 2002). Type II cystatins are mostly secreted into bodily
fluids and plasma. They often function in the protection against micro-organisms that use
C1 proteases to invade the body. They also regulate the function of C1 protease that operate
extracellularly, for example, cathepsin-B in the process of bone resorption. The role of the
cystatin inhibitory units on kininogen is not clear yet. One well documented function of phy-
tocystatins is the inhibition of C1 proteases in the gut of herbivore insects. This prevents the
digestion of plant proteins by the insect; thereby protecting the plant. The cystatins, although
reasonably well-studied are not understood as well as the proteases that they inhibit.
1.4.6 Clinical significance
Cystatins are important in various diseases and clinical applications. Some examples are
given below:
• Plasma levels of Cystatin-C serves as an indication of glomelar filtration rate in the
kidneys. This is used as a diagnostic for kidney damage (Mussap & Plebani, 2004).
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• The interaction between cystatin-C and cathepsin-B plays a role in the spread of many
types of cancer (Mussap & Plebani, 2004).
• Certain mutations in cystatin-C lead to amyloid formation and cerebral hemorrhage
(Abrahamson, 1988).
• Mutations in cystatin-B are thought to be responsible for progressive myoclonus epilepsy
(EPM1) (Pennacchio et al. , 1996).
• Imbalances between cystatins and cystein proteases play a role in various diseases in-
cluding osteoporosis, rheumatoid arthritis and Alzheimer’s (Vasiljeva et al. , 2007).
• Certain parasitic nematodes use cystatins to modulate of the host immune response
(Hartmann & Lucius, 2003).
Unlike with the C1 proteases there have been no attempts to target cystatins with drugs. The
clinical application of cystatins is currently limited to diagnostics.
1.4.7 Economical significance
The industrial use of cystatins is currently limited. There is, however, some interest in cys-
tatins in the biotechnology sector in agriculture.
Phytocystatins play an important role in defense against some herbivorous insects. After
ingestion by the insect, the inhibitor blocks the digestive enzymes of the insect in the insect
gut. This leads to reduced growth or death for the insect. Much has been published on the
topic recently (Martinez & Diaz, 2008). There are various attempts to utilize this process in
biotechnology to make crops more resistant to pests.
1.4.8 Available data
The cystatins are a well-known and well-documented group, having been studied for over
40 years. There are over 950 unique sequences of cystatins in the Pfam (Finn et al. , 2010)
database and over 33 experimental structures in the PDB (Berman et al. , 2000).
1.5 Chagasin-like inhibitors
1.5.1 Summary
Chagasin-like inhibitors are a recently discovered family of protein inhibitors of C1 proteases
that was first identified in Trypanosoma cruzi (Monteiro et al. , 2001). Homologs were later
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identified in many different organisms ranging from archea, eubacteria and eukaryotes (Rig-
den & Mosolov, 2002). The only known molecular function is the inhibition of C1 proteases.
Very little is known about the actual physiological processes they are involved in. Since the
protein family is widely distributed amongst different organisms, implying a long evolution-
ary time-period, it is likely that the members have adapted to play a variety of physiological
roles. Several experimental structures have been published and chagasin-like inhibitors share
a striking similarity to cystatins in the regions interacting with the protease.
1.5.2 History
The discovery of chagasin was announced in 2001. In that same year, based on secondary
structure prediction and threading, it was correctly postulated that chagasin has an immunoglobin-
like fold (Monteiro et al. , 2001). The discovery sparked strong interest in the research com-
munity. Soon after, in 2002, a list of homologs discovered in other species were published;
along with an analysis of the conserved residues and possible mechanism of interaction with
the protease (Rigden & Mosolov, 2002). The first experimental structure was an NMR struc-
ture published in 2006 (Salmon et al. , 2006). A monomeric crystal structure (Da Silva et al. ,
2007) and several crystal structures of chagasin in complex with different proteases followed
(Ljunggren et al. , 2007; Wang et al. , 2007; Redzynia et al. , 2008).
1.5.3 Classification
As a protein inhibitor of a protease, chagasin-like inhibitors are classified in the same schema
as the cystatins. See subsection 1.4.3 for an explanation of the classification schema. Chagasin-
like inhibitors have been assigned to clan JL and family I42. There are no subfamilies defined.
1.5.4 Structure and function
Chagasin has an immunoglobin-like fold. It has two β-sheets, each containing three β-strands,
lying on top of each other. As with cystatin, the interacting parts lie in the loops that connect
the secondary structure elements. The inhibition mechanism is strickingly similar to that of
the cystatins. Three separate loops bind to the active site groove in exactly the same places as
the three loops of the cystatins. The inhibitor physically blocks access to the active site. Like
the cystatins, chagasin-like inhibitors are tight-binding, reversible, competitive inhibitors.
See to Figure 1.3 for a visual representation.
1.5.5 Biological roles
Not much is known apart from the fact that chagasin-like inhibitors are inhibitors of C1
proteases. There are likely a wide variety of functions, based on the wide distribution of the
protein family and the wide variety of functions of C1 proteases.
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Figure 1.3 – Molecular structure of chagasin (PDB ID: 3E1Z) in cartoon representation. The
protease (papain) is shown in surface representation in blue with the catalytic cysteine in purple.
Chagasin is shown in cartoon representation. As with cystatin, the backbone of the inhibitor turns
away from the protease at the catalytic cysteine residue.
1.5.6 Clinical significance
Chagasin-like inhibitors are present in many bacterial and protozoan pathogens. This includes
Trypanosoma, Leishmania, Entamoeba, Pseudomonas, Clostridium, Coxiella and Plasmod-
ium spp. (Rigden & Mosolov, 2002; Pandey et al. , 2006). Some specific examples of involve-
ment in disease are chagasin itself, shown to be a virulence factor in Chagas disease (Santos
et al. , 2006), and falstatin, a distant homologue of chagasin from Plasmodium falciparum,
shown to facilitate erythrocyte invasion during malaria (Pandey et al. , 2006). Because of
the important roles of many C1 proteases in pathogenic diseases it is thought chagasin-like
inhibitors may also have important functions. A chagasin homolog has not been identified in
humans. Currently there are no clinical uses for chagasin-like inhibitors.
1.5.7 Economical significance
It was shown that, similarly to cystatin, chagasin can inhibit the digestive enzyme of bean
weevil larvae and cause mortality and reduced growth amongst them (Dos Santos Monteiro
et al. , 2008). This is aimed at the creation of genetically modified, weevil resistant, crops.
Further than that, the known economical significance of these proteins are limited to the cost
of the diseases they are involved in.
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Figure 1.4 – Comparison of the molecular structures of cystatins and chagasin-like inhibitors.
Cystatin-B (PDB ID: 1STF) is shown in blue and chagasin (PDB ID: 3E1Z) in red, both in cartoon
representation. The protease, shown in green, is papain from 1STF. The orientation of chagasin
to the 1STF structure is based on the superpositioning of the proteases in the two experimental
structures (papain in both).
1.5.8 Chagasin-like inhibitors of malarial proteases
In 2006 a paper was published, identifying a very remote homolog of chagasin in P. falci-
parum (Pandey et al. , 2006). The name, falstatin, was given to the protein and it was shown
to be required for erythrocyte invasion, a critical step in the parasite lifecycle. The exact
function and interaction partner of falstatin remains unknown but it evidence suggests that it
interacts with cysteine proteases of the host parasite to prevent apoptosis (Rennenberg et al. ,
2010). Falstatin is much bigger than chagasin and contains N-terminal signal sequences and
additional inserts.
1.5.9 Available data
The chagasin-like inhibitors have only been discovered recently (2001), yet there are already
roughly 170 sequences in Pfam (Finn et al. , 2010) and 10 structures in the PDB (Berman
et al. , 2000). While not as much data as for the cysteine proteases or cystatins, this is enough
for the purposes of this study.
1.6 Comparison between cystatin and chagasin
Cystatin and chagasin are both protein inhibitors of C1 proteases. The overall structure of
the cystatins and the chagasin-like inhibitors differ completely but there is almost perfect
structural similarity between the interacting loops of the two proteins. See Figure 1.4 for a
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visual comparison of the two inhibitor families. The similarity between the binding loops of
cystatins and chagasin-like inhibitors is a truly remarkable case of convergent evolution. The
function of the proteins are carried out solely by these interacting loop and the rest of the
protein serve only to hold these loops in the correct orientation. Thus, two different scaffolds
evolved independently, yet perform the same function using the same method.
Cystatins are more widely distributed amongst different phyla than chagasin-like inhibitors.
Cystatins predate animal and plant divergence since they are found in both kingdoms. Cha-
gasin is more narrowly distributed and has so far only been discovered in parasites of ani-
mals. Combined with the fact that chagasin has an immunoglobulin-like fold this has led to
the hypothesis that chagasin arose from a horizontal gene-transfer event, from host to parasite
(Rigden et al. , 2001).
1.7 Computer-based protein structure prediction
A protein’s function depends on it’s structure. Therefore, knowledge of a protein’s struc-
ture is useful in understanding how a protein carries out it’s function on a fundamental level.
Furthermore, structural information can be used to guide biochemical experiments like mu-
tagenic studies and reduce the amount of laboratory work that is necessary to characterize a
protein (Zhang & Kim, 2003). It is also useful when designing molecules that interact with
the protein. Structure based drug design is one way of obtaining drugs that target specific
proteins and requires structural knowledge of the drug-targets. Although most drugs are still
derived from natural sources, it can be argued that as the drug-design techniques improve,
it will become more economical to use structure-based drug design. There is hope that the
usefulness of knowing a protein’s structure will improve over time as the tools to make use
of the information improves (Andricopulo et al. , 2009).
Determining the 3D structure of a protein through experimental procedures is expensive,
although the structural genomics project has reduced the cost somewhat (Pusey et al. , 2005).
There are currently two main technique of experimental structure determination that account
for over 99% of experimentally determined protein structures.
The first and oldest technique uses X-ray diffraction (Kendrew et al. , 1958) to infer the
structure of a protein. The protein is crystallized and then used to diffract X-rays from an
X-ray source. The diffraction pattern is then used to infer the structure of the protein via
complex mathematical equations.
The second technique uses nuclear magnetic resonance (NMR) to create a set of spatial con-
straints used to solve the structure of the protein (Wuthrich, 1989). NMR refers broadly to
the use of magnetic fields and electromagnetic radiation to detect energy shifts caused by
interactions between atomic nuclei and electrons in the protein due to their magnetic spin.
The results are obtained as a spectrum of frequencies where the protein interacts with the
electromagnetic radiation. These clues are then used to reconstruct the protein structure.
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A third technique, utilizing electron microscopy, is gaining traction and is mainly used for
getting low resolution structural information about very large proteins. As there are no cys-
teine protease structures or any of their inhibitors determined with this technique, it will not
be discussed further.
Both X-ray diffraction and NMR have important limitations. In the case of X-ray diffraction,
purification of sufficient protein and subsequent crystallization is difficult and sometimes
impossible with very large proteins. Another problem is that a structure obtained through
the use of X-ray diffraction represents the protein conformation in a crystallized form; which
is often not the same as that of the functional protein in physiological conditions. With
NMR, the main problem is that interpretation of the raw NMR data is very difficult. In large
molecules it becomes impossible to reconstruct the protein structure from the spectrum. As
such, NMR is limited to small proteins.
Computer-based structure prediction refers to the theoretical prediction of protein structures
based on their sequence, using the computational power of computers. Since it was shown
that a protein’s sequence determines its 3D structure (Anfinsen & Haber, 1961), attempts
have been made to unravel this causal relationship. Computer-based structure prediction is
the only viable method addressing the problem.
There are two main branches of the discipline namely de novo (also called ab initio) mod-
elling and homology modelling. Software can be classified into one of these branches based
on the information that it uses to make the structural prediction. If the program uses exper-
imentally derived structural information about a homologous protein, then it is classified as
homology modelling. Otherwise it is considered de novo. Apart from homologous protein
structures, several other sources of information are incorporated into the predictions. This in-
cludes physics based energy functions and force fields as well as statistical potentials derived
from the knowledge base of all solved protein structures (Moult, 2005).
All computer-based structure prediction contains two important elements, namely conforma-
tional search and conformational evaluation. No matter what the algorithm, these two ele-
ments are always present. Viewing computer based structure prediction programs within this
paradigm is very useful as it makes comparisons between different programs and techniques
sensible.
The average protein contains thousands of atoms and each atom has three spatial dimensions.
Thus, there are typically thousands of variables involved when specifying a protein structure.
Proteins thus have an extremely large range of theoretically possible conformations (con-
formation space). Effectively sampling this huge space and reliably evaluating the sampled
conformations in terms of their thermodynamic favorability is, in essence, what all computer
based structure prediction software tries to do.
To monitor and evaluate the software used to produce structural models of proteins, a major
project was created in the form of a structure prediction competition called ”Critical Assess-
ment of Techniques for Protein Structure Prediction” (CASP) (Moult et al. , 1995). Proteins
whose structures have been experimentally determined, but not yet published, are designated
as targets for computer based prediction. Entering teams then submit predictions for some
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or all of the target proteins. The submitted models are then compared to the experimental
structures to determine which models were the best. The competition has been running since
1994 and is held every second year. A website dedicated solely to this competition can be
found at www.predictioncenter.org. CASP is the main source of information comparing the
accuracy of different modelling techniques and programs.
The results of CASP show that de novo modelling is steadily improving but cannot currently
provide reliable results for anything but very small proteins (Ben-David et al. , 2009). There
are still insufficiencies in both the conformational search, and the identification of native
conformations amongst the sampled conformations. Although the use of special-purpose
hardware like Anton (Shaw et al. , 2007) can dramatically speed up molecular dynamic sim-
ulations, access to such computers is limited and expensive. Homology modelling, on the
other hand, can produce accurate, reliable and cheap results on commodity hardware, but is
limited by the availability of experimentally determined structures of homologous proteins
(Kryshtafovych & Fidelis, 2009).
1.8 Homology modelling
1.8.1 Introduction
Homology modelling refers broadly to the practice of creating a structural model of a protein
(target) by using experimentally obtained, structural, information about a homologous pro-
tein (template). The idea dates back to the early 80’s, before the wide-spread use of comput-
ers, when it was pioneered with mammalian serine proteases using physical models (Greer,
1981). It relies on the conservation of protein structure during evolution (Chothia & Lesk,
1986). Finding sequence similarity between proteins practically guarantees that there will
be structural similarities. The structural information allows the program to limit the confor-
mational search to conformations that resemble the homologous protein, reducing the search
space immensely. Depending on the evolutionary distance between the target and template,
highly accurate models can be produced (Read & Chavali, 2007). Some have even been used
for drug-design purposes (Hillisch et al. , 2004).
Like with the experimental methods, there are certain limitations to using homology mod-
elling. Homology modelling can only be used if the structure of at least one closely related
protein is known. Furthermore, it is difficult to know how accurate a model is after it is built,
although a good estimate can be made based on the sequence similarity to the template.
Homology modelling increases information recovered from the experimental methods. By
determining the structure of just one protein it is actually possible to get information about
the structures of many, related, proteins. It is hoped that homology modelling will be used,
in the near future, to provide reliable structural information about all sequenced proteins and
close the gap between sequence and structure data (Zhang & Skolnick, 2005).
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Figure 1.5 – Flow diagram of homology modelling process. Data is shown in blue rectangles
and processes are shown in red ovals. Blue arrows represent input into a process and red arrows
represent output.
1.8.2 Process overview
The process described here is the traditional homology modelling approach. Many variations
exist, but the process outlined here is still a useful representation of the process.
The protein being modelled is called the target. The related protein, or proteins, with ex-
perimentally determined structures are called the template, or templates, because its structure
serves as a template for that of the target protein. The method involves four main steps (Moult
et al. , 2007; Sanchez & Sali, 1997; Xiang, 2006):
(See Figure 1.5 for a graphical presentation)
1. Homolog identification: The first step in applying homology modelling is to find suit-
able experimental structures on which to base the new model. This step relies on the
existence of a homolog with known structure as well as the ability to find it. Vari-
ous search algorithms have been implemented in computer programs and are used for
this purpose. These are the same as those used to detect homology in other research
applications. Currently the most widely used search tools are based on the BLAST al-
gorithm and variations of it (Altschul et al. , 1997). Depending on the specific method
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that will be used to construct the model, one or more homologs are chosen to serve
as templates. Structures are mostly extracted from the PDB database (Berman et al. ,
2000).
2. Alignment: The sequence of the target protein is aligned to that of the template protein
or proteins. Alignments can be performed by submitting sequences to a program or
webserver that return sequence alignments (Pei et al. , 2008; Notredame et al. , 2000).
There have been many recent improvements in alignment software and manual editing
of alignments is usually not required. The alignment step is critical to the success of
a homology modelling attempt. Any errors in the alignment of target and template are
likely to lead to large errors in the final model. Alignment of distant homologs can
be improved by using multiple sequence alignments, Hidden Markov Models (HMM),
profile alignments or using structural information (Jimin, 2008).
3. Model creation: The model is built by submitting the alignment of the target and tem-
plate protein, from step 2, to a modelling program along with the structure of the tem-
plate protein or proteins. The program then constructs a model of the target protein.
Different programs have different methods of incorporating the information from the
homologous protein structure. There are also different methods of searching the confor-
mational space and evaluating individual conformations. Sometimes they have several
evaluation functions that are used in different stages of the model building process.
Physical energy, stereo-chemistry, similarity to known protein structures and similarity
to the template are the main criteria used in the evaluation functions. Putative model
generation techniques include steepest descent optimizations, genetic algorithms and
Monte Carlo techniques (Sali & Blundell, 1993; Petrey et al. , 2003; Wallner & Elofs-
son, 2005; Misura et al. , 2006; Xiang, 2006).
4. Model validation: The model is evaluated using several tools to try and find any er-
rors and estimate the accuracy of the model. Different tools may be used to analyze
different aspects of the model. The evaluation tools usually give a score that indicates
how ”normal” a model is compared to known protein structures. For example, bond-
lengths, bond angles, angle combinations and inter-atomic packing are all parameters
that may be evaluated (Kryshtafovych & Fidelis, 2009). If errors are found, they may
be corrected and re-evaluated. Step 4 is important and can also be used to select a
model from a set of putative models. Different applications of protein models require
different levels of accuracy. It is therefore important to assess the accuracy of models
so that they are not used for a purpose for which they are not accurate enough. The
accuracy of homology models can vary from completely wrong (ie, wrong fold) to
highly accurate models, almost as good as an experimental structure. The true level
of similarity between the model and true protein is best estimated from the sequence
similarity between the template and target proteins (Kryshtafovych et al. , 2011). In-
formation about the divergence of sequence and structure (Chothia & Lesk, 1986) is
very useful in making this estimation. There is ongoing efforts to try and find better
ways of estimating model accuracy (Benkert et al. , 2011).
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1.8.3 Modeller
Modeller was the program choses for performing homolgy modelling in this project. The
reasons for choosing modeller above other packages are mainly speed, a proven track-record
and ease of use.
Modeller (Sali & Blundell, 1993) is a program that is very commonly used to produce ho-
mology models. In over seventeen years of existence, it has been continuously updated and
expanded. Today, it is a structural biology toolbox that also provides functions for sequence
alignment, structural superpositioning and more. Regular updates are released and there are
very few bugs in the program. It is free to use to academic and non-profit institutions but
requires registration (free of charge) to download the program. Modeller can be obtained
from http://salilab.org/modeller.
Modeller uses optimal satisfaction of spatial constraints to produce homology models. Spatial
constraints are represented as probability density functions (pdf) to describe a specific spatial
feature. A pdf indicates the probability that a specific variable will have a certain value.
Different pdfs will put different constraints on the variable. By applying various pdfs to all
the atoms in the protein, certain patterns and rules can be enforced on the position that the
atom is allowed to take.
By examining known protein structures, various such pdfs were determined for many fea-
tures within proteins. To apply certain pdfs to only specific atoms, conditional pdfs were
implemented. Conditional pdfs are only applied if the conditions attached to it are met. For
example a conditional pdf will provide information about a bond-length only if the two atoms
involved are both carbon. Each conditional pdf may have multiple conditions, combined with
Boolean logic. For example instead of treating all carbon-carbon bonds the same, a pdf can
be used that applies to a specific carbon-carbon bond. For instance the bond between the
α−carbon and the carboxyl carbon will have its own pdf and the bond between the α−carbon
and the sidechain β−carbon will have another. There are many characteristics that may be
described by pdfs, some examples that are used by Modeller are bond-lengths, bond-angles,
dihedral angles, and non-bonded inter-atomic distances.
To use information from the template structure, some characteristics of its structure are con-
verted into pdfs. Information from many known protein structures are combined with that
from the template to do this. This is because it is impossible to generate a pdf from a sin-
gle observation. Information about distribution shapes and variances from large numbers of
proteins is combined with the single observation from the template to create each pdf.
Features in the protein are described by more than one basic pdf and these are combined by
weighted summation or multiplication, where appropriate, to give feature pdfs. The feature
pdfs listed in the article are:
• Cα-Cα distance restraints
• Main-chain N-O distance restraints
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• Stereo-chemical restraints
• Main chain conformation restraints
• Side-chain dihedral angle restraints
These exist for every instance of the feature in the protein separately.
To find a model that optimally satisfies all the pdfs, the feature pdfs are combined into one
single molecular pdf. This function is a multidimensional (3N dimensions where N is the
number of atoms) scalar function. The values or coordinates that maximizes this function
corresponds to the coordinates of the atoms in the model that optimally satisfies all the feature
pdfs. To combine the feature pdfs into one molecular pdf, they are simple multiplied with
each other. This gives the function that is to be optimized.
An iterative approach (where the conformation of the protein is repeatedly adjusted) is used
to optimize the function where at fist only very short range terms are optimized and the
successive steps increases the range of terms included until all the terms are included. The
optimization uses another transformation: F = − log(P). The function F is called the ob-
jective function and has a minimum where the molecular pdf has a maximum. However the
function F is more friendly to computations since the log function transforms product terms
into sum terms.
A conjugate gradient method is used to find the minima during each step, using the answer
from the previous step as the starting point for the next step. After all the steps are com-
plete and the molecular pdf have been optimized, the point in multidimensional space that
optimizes the molecular pdf defines the structure of the protein. From this point, further re-
finements to the protein structure are made, depending on the options specified by the user.
This can include short molecular dynamics runs and simulated annealing.
1.9 Protein-protein interactions
Proteins often act together by binding to each other. These interactions ranges from transient
interactions to permanent binding for the lifetime of the protein. The binding of one protein
to another can change the functional activity of the proteins. This change can be as small as
a slight change in the kinetics of an enzyme or as big as changing the catalytic reaction of
the enzyme completely. Some enzymatic functions can only be carried out when several pro-
teins combine to form a multi-protein complex. The same forces that govern protein folding
also govern those of protein-protein interactions. Hydrophobic interactions are indicative of
permanent associations between proteins whereas hydrogen bonds and electrostatic interac-
tions indicate temporary association often dependent on environmental conditions such as pH
(Jones & Thornton, 1996). There are various ways to predict the structures of protein-protein
complexes. The term docking is often used for the process of predicting structures of protein
complexes. For the sake of clarity, in this document, the phrase homology modelling will
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be used to refer to the prediction of complex structures using information from the known
structure of an evolutionary related complex. The term, docking, will be used for all other
methods of predicting protein complex structures (this includes methods that make use of
homologous monomer structures).
1.9.1 Docking
Docking is a term used broadly for the prediction of binding conformations of ligands to
proteins. In the case where the ligand is a protein it is often referred to as protein-protein
docking. There exists a vast array of different techniques and approaches for docking (Vakser
& Kundrotas, 2010). They utilize physical forcefields, statistical potentials and complemen-
tary spatial conformations, amongst other, to predict binding positions. Docking traditionally
relies only on structural knowledge of the monomers that combine to form the complex.
The monomeric structures are then combined through the docking process to give a complex
structure. For docking to be feasible, the structures of the binding partners needs to be known
quite accurately. There are many cases where homology models are sufficiently accurate to
be used for docking (Tovchigrechko et al. , 2002). In cases where the proteins have the same
conformation in the monomeric (unbound) and complex (bound) form, accurate predictions
of the complex structure are generally possible. To improve the accuracy of docking attempts,
and reduce the computational expense, it is helpful to use additional information to limit the
number of possible conformations considered. Experimental data that implicate or exclude
certain residues in the binding of the proteins is a common type of such information.
A recent paper (Vajda & Kozakov, 2009) identifies three main classes of docking programs
based on the approach used. These are fast Fourier transforms (FFT), medium range Monte
Carlo methods and restraint-guided high-ambiguity driven biomolecular docking (HADDOCK).
Leading programs implementing each is ZDOCK (FFT), RosettaDock (Monte Carlo) and
HADDOCK, which is also the name of a program. These methods utilize different source
of information and are suited to different docking problems. FFT programs are best suited
to, and perform best at, global searches, where there is no prior information about binding
location is known. It uses a simplified representation of the protein surface to find com-
plementarities in shapes of the two proteins. Monte Carlo techniques are very expensive
computationally and are therefore unsuitable for global searches. They excel at optimizing
local conformations and making refinements to conformations that are already close to the
native structure. HADDOCK type docking excels when there is prior knowledge of the bind-
ing interface that can be used to guide the docking attempt. HADDOCK can produce good
results even with significant conformational changes upon binding.
A similar project to CASP was launched for protein-protein complexes in 2001 (Janin et al. ,
2003). The Critical Assessment of PRedicted Interactions (CAPRI) follows the same princi-
ple as CASP in setting targets with known, but unpublished, structures. Steady progress has
been observed over the duration of the competition (Lensink & Wodak, 2010).
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1.9.2 Homology modelling of protein complexes
Applying the homology modelling methodology to protein-protein complexes is a relatively
new approach (Kundrotas & Alexov, 2006; Kundrotas & Vakser, 2010). It has exactly the
same steps as the normal homology modelling method for monomers. This is a relatively
new approach for complexes because the number of experimentally solved complexes has
only recently become high enough to make this approach feasible in a significant number of
cases (Hwang et al. , 2008). There is still relatively little information available in the liter-
ature regarding the efficacy of this approach. Results published so far, including from this
study (Tastan Bishop & Kroon, 2011), are promising. Theoretically, homology modelling
should be able to provide better results than docking, since more information is utilized to
make the prediction. In fact, homology modelling can be seen as a special case of docking
where information from a homologous complex is used to limit the conformational search.
However, docking techniques and homology modelling techniques have followed separate
development paths and the implementations of the two approaches differ markedly. Since the
divide between homology modelling and docking is only artificial, from a theoretical view-
point, it is possible that a convergence of the techniques will take place (Vajda & Kozakov,
2009). The docking methods typically spend more time in optimizing the orientation of the
monomer structures relative to each other while homology modelling usually leaves the po-
sition of the backbone atoms as close to their position in the template as possible. Homology
modelling is much less time consuming than docking implementations, as a much smaller
conformational space is searched.
1.10 Data and databases
For the sake of convenience, most biological sequence and structure data are saved in online
databases, so that the data can be obtained easily. A list of the databases used in the current
project is given here.
1.10.1 UniProt (www.uniprot.org)
UniProt (One protein) is a curated database that aims to store rich information about all
known proteins. Its most valuable feature is that it is non-redundant and only has one database
entry for each individual protein. That makes it very useful to get reliable and up to date
data on a specific protein. It provides sequence data as well as annotation for each protein
including post-translational modifications, literature references and links to other databases,
including the PDB (Apweiler et al. , 2010).
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1.10.2 Protein Data Bank (PDB, www.pdb.org)
The PDB is the main database for experimentally determined protein structures. Each struc-
ture is given a four letter code (made up of letters and numbers) which uniquely identifies the
structure. This code is called the PDB ID and is used throughout this study to refer to specific
experimental structures (Berman et al. , 2000). By going to the website address given above
and entering the PDB ID in the search box, the original structure and information relating to
it can be found.
1.10.3 MEROPS (merops.sanger.ac.uk)
MEROPS is a database exclusively dedicated to proteases and their inhibitors. It provides
a classification schema and assigns clan and family names. It also has a list of members of
each family with links to other databases and literature (Rawlings et al. , 2010).
1.10.4 Pfam (pfam.sanger.ac.uk)
Pfam (Protein family) provides alignments of protein families. It also provides phylogenetic
trees showing the distribution of the members of each family in the living kingdoms. Pfam
draws its sequences from the UniProt database. New sequences are regularly and automati-
cally added to the existing families. Because it is automated, it is very up to date (Finn et al.
, 2010).
1.11 Summary
The C1 protease family and its protein inhibitors are relevant research topics. These pro-
teins are important for medical research, agriculture and even biochemistry research itself.
The C1 proteases are also a very well characterized protein family with many sequences and
experimental protein structures available. This large amount of experimental data enables
computational methods to be used that are not feasible for most protein families. One spe-
cific computational approach, that is explored further in this project, is the use of homology
modelling to predict the 3D structures of protein-protein complexes. This has the advantage,
over conventional docking procedures, of much lower computational cost while maintaining
very high accuracy.
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Chapter 2
Project design and rationale
2.1 Chapter overview
This chapter aims to give the reader insight into the overall rationale and experimental design
of the project. It also provides technical details about the protocols and programs that do not
fit into one particular part of the project but was important throughout. Some terminology is
also introduced to simplify discussion later on. The project aims and motivation are given
first (Section 2.2), as this provides context to the rest of the chapter. The experimental design
of the entire project is then described without much technical details (Section 2.3). This is
followed by technical details of the homology modelling done in the project, including the
calculation of scoring functions and energy minimization (Section 2.4). The chapter ends by
providing discussions of technical considerations of the data management, software, used in
the background, throughout the project and computational resources used. (Section 2.5 and
2.6).
2.2 Project aim and motivation
The main research question addressed in this study was whether templates constructed by
combining coordinates from different experimental structures, using superpositioning, can be
used to construct accurate models of C1 protease-inhibitor complexes.
This question was addressed by generating such templates and using them in a homology
modelling pipeline and comparing the results to those achieved by using traditional tem-
plates in the same pipeline. The accuracy of both of sets of models were estimated by using
established accuracy metrics. Various techniques to improve model quality were used both to
evaluate their effectiveness and to evaluate their suitability for models based on the two types
of templates.
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Additional research questions addressed are whether C1 proteases and/or their protein in-
hibitors undergo conformational change upon complex formation, how to select the best tem-
plates for homology modelling of C1 protease-inhibitor complexes and how accurate the
models are.
The original aim, when the project started, was to accurately model, and then analyze, sev-
eral complexes of cysteine proteases and protein inhibitors that were of interest due to their
role in disease and biotechnology. It became clear that if this was to be done for a large
number of complexes, homology modelling would be the best technique to use. Although
not well established for the use of predicting protein complex structures, homology mod-
elling is a better choice than traditional, monomer-based, docking techniques in this case.
The reason is that there are several experimentally determined complex structures of cysteine
proteases with protein inhibitors available. Given these structures, the matter of orientation
between monomers become a trivial issue, and the main focus of the modelling attempt must
be the correct prediction of the monomer structures and the refinement of the interface re-
gions. While medium range Monte Carlo docking methods and HADDOCK (Section 1.9.1)
could also be used for this purpose, homology modelling has the added benefit of very low
computational requirements and easy incorporation into automated protocols.
Once the decision to use homology modelling was made, the next question was which tem-
plates to use. There are well studied criteria for the modelling of monomers, but for com-
plexes there was little information to be found regarding how to prioritize the sequence sim-
ilarity of the separate monomers when a choice of template was to be made. The problem
could be avoided altogether if the best template for each component of the complex could be
selected from different experimental structures. This removes the need to compromise on the
sequence similarity of the individual proteins. A very simple way to do this is to superimpose
the experimental structures onto each other, based on the common parts, and then copy the
coordinates for the individual components from the superimposed version of the structures.
In this way, a hybrid template is formed that contains components from two separate experi-
mental structures. This has not been done before and, as such, the approach carries some risk
as the reliability of such templates has not been verified in previous studies.
In order to answer the question of which templates were the most suitable and whether hybrid
templates could be used, a separate study was launched that became the main focus of the
project. The aim of this study was to directly compare the accuracy of models based on hy-
brid templates to those based on single-experimental-structure templates (simple templates)
and elucidate the relationship between the sequence similarity of the monomers and the ac-
curacy of the complex model. As part of this investigation, the effect of energy minimization
to improve the accuracy of models and the ability of scoring functions to identify accurate
models were also investigated. The modelling of a large number of cysteine protease com-
plexes with protein inhibitors was still carried out, but, due to time constraints, the analysis
of these models was scaled down from the originally intended analysis.
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2.3 Experimental design
The project comprises four main parts. Three parts are experimental in nature, with the
fourth forming part of the results presentation. The first part involves the examination of
experimentally solved protein structures. The second involves the modelling of complexes
with known experimental structures to evaluate the accuracy of models built on different
templates. The third follows from the second, and uses its results to select templates for, and
model, several novel complexes. The last part consists of the creation of a website to provide
access to all the raw data of the project in a useful way.
2.3.1 Part 1: Examination of experimental structures
In the first part, some experimental structures (Table 3.1) of all the protein families involved
in the project were investigated. One of the major aims of this study was to test if any of the
proteins undergo conformational changes upon binding. Such conformational changes would
have very important implication for the selection of templates, as conformational changes are
not accurately modelled using homology modelling. The other major aim was to examine
the variation that exists between different crystal structures as a measure of what accuracy
could realistically be achieved using homology modelling. Calculation of RMSD values and
visual inspection was used as the main investigative techniques. The study also provides
some information about the differences between the subfamilies that was beyond the scope
of the introduction. A detailed description of the methodology followed is given in Chapter
3.
2.3.2 Part 2: Construction and evaluation of test set models
In the second part of the project, many models were built, and evaluated, in order to ad-
dress the issue of template selection for the modelling of complexes as explained in Section
2.2. To directly compare the accuracy of different models, an objective measure of accu-
racy is needed. To accomplish such objective measurement, this part of the project was
modelled on the CASP and CAPRI competitions. Models of complexes, with known ex-
perimental structures, were built and then compared to the experimental structures using ob-
jective metrics used in CASP and CAPRI. The effect of energy minimization using Rosetta
(www.rosettacommons.org) all atom minimization and the ability of two different scoring
functions (Rosetta energy and DOPE Z-score) to identify high-accuracy models were also in-
vestigated. The reason for the evaluation of the scoring functions is that they offer important
benefits to the homology modelling process. In most homology modelling protocols, several
varying models are produced because of differing random numbers used in their construction.
In a high-throughput setting, scoring functions are a viable selection tool that can be used to
select the final model out of a set of candidates, thereby giving a more accurate final model.
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Table 2.1 – Experimental structures used as the test set targets. These structures were also used
for the generation of templates. Shown is the PDB ID as well as the name and species of origin
for the protease and inhibitor of each structure.
PDB ID Protease Organism Inhibitor Organism
1NB5 Cathepsin-H S. scrofa Cystatin-A H. sapiens
1STF Papain C. papaya Cystatin-B H. sapiens
1YVB Falcipain-2 P. falciparum Ovocystatin G. gallus
2NQD Cathepsin-L H. sapiens Chagasin T. cruzi
2OUL Falcipain-2 P. falciparum Chagasin T. cruzi
3CBJ Cathepsin-B H. sapiens Chagasin T. cruzi
3E1Z Papain C. papaya Chagasin T. cruzi
3IMA Papain C. papaya Tarocystatin C. esculenta
3K9M Cathepsin-B H. sapiens Cystatin-A H. sapiens
The effect of minimization was also studied since it offers the possibility of further improving
on model accuracy.
The PDB was searched for experimental structures of complexes between C1 proteases and
cystatins or chagasins that could be used as targets for the test set models. Nine such com-
plexes were identified using keyword and BLAST searches. These structures can be viewed
in Table 2.1. Each of these targets were then modelled and evaluated, using all available
templates as described in section 2.4, to determine which templates gave the most accurate
models. The effect of minimization on the accuracy of the models were then investigated by
applying Rosetta full atom minimization to all the models and re-evaluating them using the
same procedure as before. For details of the evaluation and analysis of the results, see Chap-
ter 4. The models built in this part of the study, shall be referred to as the test set. Members
of this set are referred to as test models.
2.3.3 Part 3: Construction and evaluation of study set models
In the third part of the project, ten C1 proteases and eleven protein inhibitors were selected,
mostly from P. falciparum, P. vivax and H. sapiens (Table 2.2). These proteins were modelled,
in an all against all fashion, using template selection guided by the results of the evaluations
set analysis. Energy minimization and the calculation of scoring functions were also carried
out on all of the models as described in section 2.4. The set of all models produced in this
part of the project is referred to as the study set. Members of the set are called study models.
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Table 2.2 – Proteins chosen for modelling in the study set (study set proteins). *A large portion
of the falstatin sequence, including inserts near the binding loops had to be removed since there
are no templates available for these regions.
Study set
Uniprot Accession Name Organism Abbreviation
Proteases
P07858 Cathepsin-B H. sapiens Cath-B
P09668 Cathepsin-H H. sapiens Cath-H
P07711 Cathepsin-L H. sapiens Cath-L
P25774 Cathepsin-S H. sapiens Cath-S
Q9N6S8 Falcipain-2 P. falciparum FP-2
Q8I6U5 Falcipain-2p P. falciparum FP-2’
Q9NAW4 Falcipain-3 P. falciparum FP-3
Q6J131 Vivapain-2 P. vivax VP-2
Q7Z0B2 Vivapain-3 P. vivax VP-3
Q5IZD8 Vivapain-4 P. vivax VP-4
P00784 Papain C. papaya Papain
Inhibitors
Q966X9 Chagasin T. cruzi Chag
Q2PZB1 Falstatin* P. falciparum Falst
P01040 Cystatin-A H. sapiens Cyst-A
P04080 Cystatin-B H. sapiens Cyst-B
P01040 Cystatin-C H. sapiens Cyst-C
P01038 Ovocystatin G. gallus Ovocyst
Q8L5J8 Tarocystatin C. esculenta Tarocyst
P01042 Kininogen-1 H. sapiens Kini-1
P01042 Kininogen-2 H. sapiens Kini-2
P01042 Kininogen-3 H. sapiens Kini-3
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2.3.4 Part 4: Publication of results in website
In the fourth, and last, part of the project, a website was constructed in order to provide access
to all the raw data produced in the study. Since a large number of models were produced and
lots of metrics calculated, the resultant amount of data is large and allows for wider analysis
than allowed by the scope of this project. To enable other researchers to use the data, it was
made available online at http://rubi.ru.ac.za/cpmdb. For more details about the website and
its development, please see chapter 6.
2.4 Modelling overview
This section provides an overview and technical details of all homology modelling carried
out in the project. Figure 2.1 provides a graphical overview of the whole modelling process
described in this section.
2.4.1 Data retrieval
The data needed for homology modelling is the sequences of the target proteins and the se-
quences and structures of the template proteins. In the case of the test set, the structures
downloaded from the PDB, listed in Table 2.1, provides the target sequence information. The
sequence information was extracted from the structure files using a custom program (Section
2.5). The sequences of the study set proteins (Table 2.2) were downloaded from UniProt. For
both sets of models, the nine complex structures identified in Table 2.1 served as the source
of template structure information and are referred to as the experimental template structures.
The experimental template structures were identified in the PDB by manual searches using
keyword and BLAST queries. All complexes found that included a C1 protease and a pro-
tein inhibitor were included and were downloaded directly from the PDB. The sequences of
the study set proteins, shown in Table 2.2, were obtained by using keyword searches of the
UniProt database. The sequences were downloaded directly from UniProt.
2.4.2 Sequence alignment
Multiple sequence alignments of all the protein families involved were constructed using the
Promals 3D webserver (Pei et al. , 2008). One alignment was produced for the proteases, one
for the cystatins and one for the chagasin like inhibitors. The sequences of all the proteins
in the test set as well as the study set were included in this alignment. The alignment was
aided by also providing protein structures from each sub-family to the webserver. As the
alignment was expected to be highly accurate, given the availability of many intermediate
sequences as well as structural information, it was decided that the same alignment could be
used for the study set and test set models. The use of structural information from the target
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Figure 2.1 – Flow chart describing the modelling approach that was followed in the test set and the
study set. Experimental complex structures were obtained from the PDB. These nine complexes
were recombined using superpositioning to create 81 unique templates. Sequence data for the
study proteins were obtained from UniProt. The sequence data and structure data were used
together to create multiple sequence alignments for all the families in the project. The templates
and alignments were then used to build models, as shown in the figure. The colors and fonts of
the blocks indicate different proteins. Figure taken from Tastan Bishop & Kroon, 2011.
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protein, to aid alignment, when constructing test models is questionable as this provides an
unrealistically accurate alignment that would not be possible if it were a genuine modelling
attempt. However, there are so many redundant structures in the dataset that one could easily
be substituted for another. For this reason, the use of the same alignment for all models is
justified.
2.4.3 Generation of templates
Due to results from the examination of the experimental structures (Chapter 3) and to avoid
subjective decision-making, it was decided not to use any monomeric experimental struc-
tures as templates for the modelling of complexes. This left the nine, experimental, complex
structures (Table 2.1) as the only source of template structures. To construct the hybrid tem-
plates, the experimental complex structures were simultaneously superimposed using Multi-
prot (Shatsky et al. , 2004). Any extra atoms in the structures were removed. This includes
non-protein atoms as well multiple versions of proteins. Where multiple version of proteins
were present in the experimental structures, the version with the fewest missing atoms was
kept. Multiprot produces various solutions and the one with the highest number of overlap-
ping residues that contained all the experimental structures was used. Through the recom-
bination of the protease and inhibitor components from this set, 81 unique templates can be
created (Figure 2.2). This set of 81 complex structures is referred to as the template set.
Recombination is achieved by copying coordinates for the protease and inhibitor indepen-
dently from the superimposed versions of the experimental structures into a single file. Nine
of these templates (where protease and inhibitor are taken from the same experimental struc-
ture) are the same as the original experimental structures and the remaining seventy-two are
new structures that contain information from two separate crystal structures each. The nine
original crystal structures are referred to as simple templates, while those containing infor-
mation from two separate experimental structures are referred to as hybrid templates. Models
that were constructed using simple templates are referred to as simple models and those built
on hybrid templates are referred to as hybrid models.
The following naming schema, for hybrid templates, is used in the rest of the text. A hybrid
template constructed from the protease coordinates of 1YVB and the inhibitor coordinates
from 3E1Z will be referred to as follows:
H:1YVB-P:3E1Z-I
The source structure of the protease is indicated with ”-P” and that of the inhibitor with ”-I”.
Simple templates are equivalent to an actual experimental structure and can thus be referred
to by its actual PDB ID.
2.4.4 Template selection
The test set targets were separately modelled using all of the available templates that did
not contain any coordinates from the target structure. In addition, models were also built
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Figure 2.2 – Recombination of the proteases and inhibitors of the experimental template struc-
tures yields 81 different complexes. Blue colored blocks indicate templates that contain a cystatin
inhibitor and those in purple indicate templates containing chagasin. Simple templates are indi-
cated with an S and hybrid templates with an H.
using the experimental structure itself as a template. These models are referred to as self
models and serve as an estimation of the absolute maximum accuracy achievable using the
modelling protocol. See Figure 2.3 for a graphical explanation of what targets were modelled
using what templates. The result is that targets containing a cystatin inhibitor was modelled
using 33 different templates while those containing chagasin was modelled using 25 different
templates. See Figure 2.4 for the calculation of these, and other, numbers. The reason for the
difference is that there are more experimental complexes containing cystatin and therefore
more cystatin containing templates. The numbers shown in Figure 2.4 under ”per target
totals” can be obtained by counting the different kinds of available templates in Figure 2.3
and adding them up. A modelgroup refers to a set of 5 models constructed together using the
same sequence and structure information (See Section 2.4.5). They differ from each other
due the fact that random number generators are used in the construction of models. Since the
random numbers are different for every model, different models are produced. Each member
of the modelgroup thus has the same target and the same template. The combination of target
and template is unique to each modelgroup in the test set (the combination may also appear
in a different modelgroup in the study set).
In the study set, each target complex was only modelled based on one template. The template
was taken from the template set using criteria described in Section 5.3.2.
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Figure 2.3 – Templates available to cystatin and chagasin containing targets. 3IMA is given as
an example containing cystatin and 2NQD as one containing chagasin. Self templates are in-
dicated in red, with an “X”, while hybrid and simple templates are shown in blue (cystatin) or
purple (chagasin). Simple templates are indicated by a darker color and an “S”, hybrid templates
are indicated with an “H”. Templates shown in gray were not used to model the particular tar-
get. Cystatin containing targets are 1YVB, 1STF, 1NB5, 3IMA and 3K9M. Chagasin containing
targets are 2OUL, 2NQD, 3CBJ and 3E1Z.
Figure 2.4 – Total number of models built. The ”per target totals” is multiplied by the respective
number of targets to give the totals for cystatin and chagasin containing targets respectively.
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2.4.5 Modelling protocol
Given a template and target complex, the correct alignments of proteases and inhibitors are
automatically extracted from the multiple sequence alignments and used to generate a PIR
alignment (file format required by Modeller) and a modelling script using custom software
(see Section 2.5). The modelling script, PIR alignment and template structure, in PDB format,
is then submitted to Modeller 9.6 which produces 5 different models, as specified in the
script. These 5 models are referred to as a modelgroup. The reason for building 5 models
instead of a different number is that it provides enough models to get significant results while
maintaining computational time within practical limits. It is not only the computational time
of the modelling itself that has to be considered, but also that of any further processing of
the models. The default automodel routine was used with refinement set to very slow. The
modelling scripts and PIR alignments are available on the website accompanying the thesis
(http://rubi.ru.ac.za/cpmdb).
2.4.6 Calculation of scoring functions
Two different scoring functions, Rosetta energy (www.rosettacommons.org) and DOPE Z-
score (Sali & Shen, 2006), were calculated for all models produced, before and after energy
minimization. Before minimization, Rosetta energy was calculated using the ”score” pro-
gram of the Rosetta 3.1 package with the included database. The only change to the default
arguments was setting ”no_optH” to false. After minimization, the Rosetta energy is written
to a file as part of the standard procedure of the minimization protocol. Thus the score was
simply read from the file. The DOPE Z-score was calculated with the default parameters
using the ”assess_normalized_dope” function. It was calculated in the same way before, and
after, energy minimization.
2.4.7 Energy minimization
Energy minimization was carried out using the ”relax” protocol of the Rosetta 3.1 package,
using the included database. Default parameters were used. The ”relax” protocol produces
an all-atom structure, including hydrogens, by applying aggressive Monte Carlo sampling to
find conformations that minimize the Rosetta energy. The Rosetta source code and database
was downloaded from www.rosettacommons.org .
2.5 Information management
Throughout the project, programs and classes were written in the python programming lan-
guage to automate processes and thereby accommodate the high-throughput nature of the
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study. Object orientated design (software design pattern) was used and classes were cre-
ated to represent PDB structures, alignments and modelgroups amongst others. A com-
plete description of all the software written is beyond the scope of this document. The
programs allowed the programmatic manipulation of all the data. For the analysis of the
results, the data was serialized into a comma separated value file and loaded into R (http://r-
project.org). R is a powerful program designed for statistical analyses. It has powerful data-
manipulation and graphing functionality that was not afforded by the programs that were
used in the modelling process. During the creation of the website, tables were created in
MySQL(http://www.mysql.com) to accommodate some of the classes in a database form, for
fast access by the webserver.
2.6 Computational resources
The project required approximately seven thousand of hours of CPU computation. The en-
ergy minimization step in particular takes up a lot of computational time. Various computa-
tional resources were utilized. A clusters of several computers were made available by the
Chemistry Department at Rhodes University. The main bioinformatics server at Rhodes Uni-
versity and several spare computers in the bioinformatics laboratory were also used. Lastly,
toward the end of the project about twenty computers in a laboratory at the Bioinformatics
and Computational Biology Unit (BCBU) at University of Pretoria were made available. Be-
cause of the diversity of computing resources, a modular job distribution system was created.
The job distribution contains two programs, the distributor and the worker. The distributor
runs on the central computer that holds all the project data and copies the necessary files to
the computers that actually run the jobs. The worker program accepts the files, carries out
the jobs and copies the results back to the central computer. Because of different system and
network configurations, small changes were necessary to the worker program in each case.
In the case of the cluster, which had job distribution software installed, the worker program
was modified to submit the job to the queue instead of carrying out the jobs itself.
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Chapter 3
Examination of crystal structures
3.1 Chapter overview
This chapter describes an investigation of several experimental structures that are important
to this project. The chapter begins with discussion of the aim and motivation for doing this
investigation. The methods used are then described and the structures that were investigated
are listed. A short justification of how the method is connected to the achievement of the
aims is also given in the method section. The results are then given, describing differences
between the sub-families and pointing out significant conformational changes where present.
3.2 Aim and motivation
Before setting out on a high-throughput modelling project, it is prudent to first examine the
available experimental structures of the protein families involved. This will yield valuable
information for informed decision-making in template selection and provide context for the
analysis of the results. Two important questions were addressed in this part of the project.
The first question is whether the proteins undergo any conformational changes upon binding.
If there is a conformational change, then the template must be of the same state as the target
protein, i.e. for modelling complexes, the template must be part of a complex structure. If
there are conformational changes, do they vary for different binding partners? If so, then
templates can only be taken from complexes with the same class of binding partner. If not,
templates can be taken from any complex.
The second important question is that of what constitutes an accurate model. How accurately
do crystal structures represent the native protein? How much deviation from the crystal struc-
ture can be present in a model and still be regarded as having accuracy comparable to that of
a crystal structure? This is an important question as the accuracy of the models must be mea-
sured against some standard. At a certain threshold, closer similarity to the crystal structure
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is not indicative of a more native-like structure. It is important to have an idea of what that
threshold is so that models can be judged within that context.
Comparisons of the different sub-families were also carried out to give some information on
the feasibility of cross-family modelling and simply to provide some additional background
information.
3.3 Method
To investigate conformational change upon binding, experimental structures of the same pro-
tein in bound and unbound states were compared to each other. This was done for all of
the protein families involved in the project. Experimental structures to be compared were
identified in the PDB through manual searching. As a starting point, the experimental tem-
plate structures (Table 2.1) were used. These structures represent all complex structures of
C1 proteases and protein inhibitors available. As such, any protein with both monomeric and
complex experimental structures must be present in this group. The experimental structures
of every protein in that group were identified using BLAST searching. From this informa-
tion, a representative protein in each sub-family was chosen based on the number of different
structures available. Table 3.1 shows all the experimental structures that were used in this
chapter. All the structures of each protein were compared to each other. Structures were
compared using visual inspection by means of molecular visualization software as well as
calculation of RMSD values.
For the question, as to what constitutes an accurate model, multiple versions of cathepsin-B in
the same experimental structure (PDB ID: 1GMY) were compared to each other to estimate
the accuracy of the experimental structure itself. Some background information is required
to understand the rationale behind this:
When proteins are crystallized for structure determination, there are sometimes more than
one protein or protein complex per unit cell (smallest repetitive unit) of the crystal. When
the structure is then solved, the result is multiple structures of the protein or complex being
investigated. There are always some minor differences between these structures. The differ-
ence between any experimental structure and the real, native, structure of a protein can be
though of as having three different components. The first, and unavoidable, component exists
because real proteins are mobile, and this mobility can not be represented in the structure
formats (like the PDB file format) used to present protein structures. The second component
is due to conformational changes in the protein induced by experimental manipulation of
the protein. The third component is the experimental error and limitation in determining the
structure of the protein as it exists in the crystal (when using X-ray diffraction) or solution
(when using NMR). None of these components are dependent on the number of proteins in
the crystal unit cell and it is therefore reasonable to assume that these errors are reflected
in the variation between different proteins structures determined from the same crystal. The
maximum theoretical accuracy of homology models, as measured by comparison to experi-
mental structures, can be no higher than the accuracy of the experimental structure itself. In
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other words, when the variation between a model and the crystal structure of a protein is of
the same magnitude as between different conformations in the same experimental structure,
the model can be regarded as having equal accuracy to the experimental structure.
RMSD values were calculated using the McLachlan algorithm (McLachlan, 1982) as im-
plemented in the program ProFit (authored by Martin, A.C.R. and Porter, C.T, downloaded
from http://www.bioinf.org.uk/software/profit/) unless stated otherwise. All backbone atoms
were used in the calculation of RMSD values. Figures were created using PyMOL (DeLano,
2002). The superpositioning shown in the figures (superpositioning performed by PyMOL
algorithm) is not always the same as that used for calculating the RMSD values. The Protein
Interaction Calculator (PIC) was used to determine which residues formed part of the inter-
face (Tina et al. , 2007). A residue was deemed part of the interface if it shows an interaction
with the other protein in any of the available experimental structures. While this method is
consistent, it leads to unequal interfaces between type I and type II cystatins because type I
cystatins have more experimental complex structures available.
3.4 Results and discussion: Papain-like cysteine proteases
3.4.1 Comparison between cathepsin-L like and cathepsin-B like sub-
families
Cathepsin-B and cathepsin-L were chosen for this comparison as they are the defining pro-
teins of the two sub-families. Figure 3.1 shows an overview of the structural differences and
similarities between the two proteins. The biggest structural difference between the two sub-
families is the presence of the occluding loop (shown in green, on the left) in members of
the cathepsin-B like subfamily. This insert is the defining difference between the subfamilies.
Apart from the occluding loop there is also a conformational difference on the opposite side
of the catalytic residues. The loop indicated in green in cathepsin-B on the right of the figure
is much closer to the active site cleft than in cathepsin-L. Given these differences, it would be
unwise to build models using a template from a different sub-family than the target protein.
3.4.2 Cathepsin-L like subfamily
Papain (C. papaya) was chosen to represent the cathepsin-L subfamily because it is the old-
est member and has the most experimental structures available. The structures chosen for
comparison can be viewed in Table 3.1.
Figure 3.2 shows the overall structure of the protein and it can be seen that there are negli-
gible conformational differences between the backbone conformations in the various crystal
structures. The side-chains also exhibit very little change and the side-chains that do differ
(TYR 61, TYR 67 and TRP 69, using sequential numbering) are solvent exposed. This means
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Figure 3.1 – A visual comparison of the cathepsin-L like and cathepsin-B like subfamilies. The
proteins shown are cathepsin-B (PDB ID: 3K9M) and cathepsin-L (PDB ID: 2NQD). Where the
proteins are the same, the backbone is colored blue. Where the proteins differ, cathepsin-B is
indicated in green and cathepsin-L in pink. The catalytic triad residues are shown in yellow.
Figure 3.2 – Four experimental structures of papain (1PPN, 1STF, 3E1Z, 3IMA) were superim-
posed and shown in the ribbon representation. The residues that contact the protein inhibitors are
shown in red with their side-chains shown in line presentation. The catalytic triad residues are
shown in yellow in stick presentation.
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Figure 3.3 – The interacting residues of 1PPN(red), 1STF(green), 3E1Z(blue) and 3IMA(yellow)
are shown in line representation and the catalytic triad in stick representation.
Table 3.2 – Backbone RMSD in Å between selected structures of papain.
1STF 3E1Z 3IMA
1PPN 0.383 0.362 0.347
1STF 0.396 0.413
3E1Z 0.382
that for modelling purposes it will not make a big difference which of the crystal structures
are used as a template.
Figure 3.3 shows a close up of the interacting residues. The structure that differs most is 3E1Z
with two side-chain changes (TYR 67 and TYR 61). In fact, two positions are specified for
TYR 67 in the 3E1Z experimental structure, one that is visible slightly to the left compared
with the other structures and one overlapping with them. With TYR 61, all the structures
show some variation so it is likely mobile. Thus, the differences between the four structures
are almost negligible.
Table 3.2 shows the RMSD values between the different experimental structures of papain
used. It shows that the most different conformations, as measured by RMSD, are those from
1STF (Cystatin-B complex) and 3IMA (Tarocystatin complex) with a value of 0.413 âDˇn´.
This is consistent with no conformational change upon binding as the monomeric conforma-
tion of 1PPN is no more different from the complex structures as they are from each other.
The 3E1Z(Chagasin) also does not show an increased RMSD when compared to the two
cystatin complexes, supporting the hypothesis that there is no conformational change when
binding to a cystatin or chagasin-like inhibitor.
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Figure 3.4 – The different conformations of cathepsin-B in 1GMY were superimposed and shown
in the ribbon representation. The side-chains of the residues that contact the protein inhibitors are
shown in red with their side-chains shown in line presentation. The catalytic triad residues are
shown in yellow, in stick representation.
3.4.3 Cathepsin-B like subfamily
Human Cathepsin-B was chosen to represent the cathepsin-B like subfamily. It is the only
member of the subfamily with experimental structures of complexed forms. The structures
chosen for comparison can be viewed in Table 3.1. There is also a monomeric experimental
structure of cathepsin-B available (1GMY) with three different conformations in the same
unit cell of the crystal.
Different conformations of the monomeric structure in 1GMY gave the opportunity to assess
RMSD variation under the same conditions of crystallization. This addresses the second aim
of this chapter as explained in Section 3.2.
Figure 3.4 shows the overall structural variation between different versions of the cathepsin-B
structure within the crystal structure 1GMY; very little is visible, as expected. If we compare
this to Figure 3.2 we see that the amount of variation is almost the same. It was also found
that the occluding loop didn’t show any more variation than the rest of the protein although
this isn’t highly visible in the figure. The implication of this is that while the occluding is
flexible, there is a clearly favoured conformation while in monomeric form.
Table 3.3 shows the RMSD between the different conformation of the cathepsin-B structure
within the crystal structure 1GMY. It is actually slightly more than between the different con-
formations of papain shown in Table 3.2. This shows that the variation between the various
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Table 3.3 – Backbone RMSD in Å between different cathepsin-B conformations of 1GMY.
B C
A 0.508 0.386
B 0.566
papain conformations is very small, but also that experimental error varies from one experi-
mental structure to the next. This deduction is made from the observation that the variation
between the papain conformations, from different experimental structures, is lower than the
variation between the cathepsin-B conformations currently under discussion. This implies
that the papain experimental structures are either more accurate or that they all have corre-
lating errors. As mobility of proteins vary from protein to protein and mobility is a large
contributor to errors in experimental structures, it makes sense that the accuracy of experi-
mental structures should also vary. Taking this into consideration, a value of 0.38Å(median
from Table 3.2 and minimum in table 3.3) will be considered a rough lower limit of the
RMSD a homology model can achieve.
Figure 3.5 shows cathepsin-B in different conformations from three experimental structures
including one monomeric structure and two complex structures. Only the first conformation
from 1GMY was used for this comparison. This relates to the aim of determining if con-
formational change takes place upon binding. Conformational change can be clearly seen
in the occluding loop when interacting with protein inhibitors. As such we cannot expect to
model the occluding loop correctly if we don’t have a template with the correct loop confor-
mation. Unfortunately there are not enough experimental structures available to determine
how much the movements varies between different inhibitors. The movement is clearly dif-
ferent between chagasin (3CBJ) and cystatin-A (3K9M); it would be informative to have a
structure with a type II cystatin, to compare the change that takes place. However, no such
experimental structure is available. This implies difficulty in the modelling of cathepsin-B
complexes.
Figure 3.6 shows a close up of the interface residues and more clearly illustrates the differ-
ences between the individual conformations of the occluding loop. In the monomeric confor-
mation of 1GMY, shown in blue, there are some residues that lie within the active site cleft
but are pushed away in both the complexed conformations to make space for the inhibitors.
It can also be seen that it is only the residues of the occluding loop (residue 109 to 126) that
undergo conformational change. The figure clearly shows that all three structures are unique
and the change induced upon binding to chagasin is different from the change upon binding to
cystatin. The implication for modelling is that there will be uncertainty of the occluding loop
conformation in any model, until more experimental structures of cathepsin-B in complex
with protein inhibitors are published.
Table 3.4 shows the RMSD between the different cathepsin-B structures. It confirms that
there is conformational change. It also indicates that the change is different in the case of
binding to cystatin-A from the change in the case of binding to chagasin. Based purely
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Figure 3.5 – Three experimental structures of cathepsin-B (1GMY, 3K9M, 3CBJ) were super-
imposed and shown in the ribbon representation. The side-chains of the residues that contact the
protein inhibitors are shown in red with their side-chains shown in line presentation. The catalytic
triad is shown in yellow in stick presentation. At the top of the figure it can be seen that there are
big conformational differences between the various structures.
Figure 3.6 – The interacting residues of 1GMY(blue), 3K9M(green) and 3CBJ(red) is shown in
line representation and the catalytic triad residues in stick representation.
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Table 3.4 – Backbone RMSD in Å between selected structures of cathepsin-B.
3K9M 3CBJ
1GMY 2.759 2.101
3K9M 2.275
on the RMSD values it seems that the conformational change is bigger for cystatin-A than
for chagasin although this cannot be used to infer anything about the affinity between the
inhibitors and the protease.
3.5 Results and discussion: Cystatin superfamily
3.5.1 Comparison between type I and type II cystatins
Cystatin-B, ovocystatin and tarocystatin was chosen for this comparison. Two type II cys-
tatins are included to highlight a slight difference between them. Figure 3.7 shows a global
comparison of the structures of the type I and type II cystatins. There are several differences
between the type I cystatins and the type II cystatins.
The main structural differences are the presence of a C-terminal extension in type I cystatins,
a bend in the α-helix of type I cystatins and an insert between the second and third β-strand
in type II cystatins. Two type II cystatins are given to show the difference between phytocys-
tatins (tarocystatin, 3IMA) and other type II cystatins (ovocystatin, 1YVB). In phytocystatins
the insert in the β-sheet is missing. Tarocystatin therefore has characteristics of both sub-
families. Since it shares more characteristics and higher sequence identity with the type II
cystatins it is classified as a type II cystatin. The differences mentioned are all visible on the
figure. The type I C-terminal extension is visible in pink on the right of the figure. The α-
helix bend can be seen on the left where the pink and green helices differ. The insert between
the second and third strands of the β-sheet is visible at the top where the type I loop is visible
in pink, the phytocystatin loop in dark-green and the type II loop in lime-green. An important
sequence difference is the presence of a tryptophan residue (residue 80, 3IMA; residue 99,
1YVB) in the C-terminal-most binding loop of type II cystatins (bottom left of the figure).
Of the four differences between the groups there are two that occur at the interface with the
protease. These are the tryptophan residue(with a very large hydrophobic sidechain) on the
C-terminal-most binding loop and the C-terminal extension. It is not shown in this figure but
the tryptophan side-chain forms extensive hydrophobic interactions with the protease during
inhibition. The C-terminal extension of cystatin-B in 1STF interacts with the protease during
inhibition and thus the type I cystatins actually have four contact points with the protease, in
contrast the three mentioned in section 1.4.4.
Modelling of type I cystatins using type II templates would lead to incorrect modelling of
the C-terminal extension while the loop on the non-interface side in type II cystatins would
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Figure 3.7 – The figure shows ovocystatin (1YVB), tarocystatin (3IMA) and human cystatin-B
(1STF). Where the proteins are the same, they are colored in blue. Where the proteins differ,
cystatin-B is colored pink while ovocystatin and tarocystatin are colored lime-green. Where taro-
cystatin deviates from the normal type II pattern it is colored in dark-green. The binding loops
are colored in red.
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Figure 3.8 – Three structures of cystatin-A (1DVC, 1NB5, 3K9M) were superimposed and shown
in the ribbon representation. The side-chains of the residues that contact the protease are shown
in line presentation in red.
be incorrectly modelled using type I templates. Whether a modelling program would be able
to account for the helix difference is doubtful and cross sub-family modelling would likely
produce an incorrect helix conformation as well.
3.5.2 Type I cystatins
Cystatin-A was chosen to present this family as there are two experimental structures avail-
able in protein complexes. Unfortunately only an NMR structure is available for the monomeric
conformation. The structures used can be viewed in Table 3.1. The single NMR structure
(1DVC) was produced by performing energy minimization on an averaged structure of the
NMR ensemble by the original publishers of the structure.
Figure 3.8 shows and overview of the three cystatin-A structures. The whole protein is some-
what flexible and shows more variation than the proteases, apart from the cathepsin-B oc-
cluding loop. Some of this difference is due to the use of an NMR structure and comparing it
to crystal structures. There is a big difference in the N-terminal (bottom right) conformation
between the monomeric structure and the complexed forms. There is even a slight differ-
ence in the C-terminal-most loop (bottom left) between the monomeric and two complexed
forms. The implications for modelling is that higher RMSD scores than for the proteases
can be expected as the protein is more mobile. It is also likely that using monomeric tem-
plates for complex structures would lead to significant errors in the interface, especially in
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Figure 3.9 – The interacting residues of three cystatin-A structures, 1DVC(green), 1NB5(red)
and 3K9M(blue) is shown in line representation.
Table 3.5 – Backbone RMSD in Å values between indicated structures of cystatin-A.
1NB5 3K9M
1DVC 2.005 1.999
1NB5 1.058
the N-terminal.
Figure 3.9 shows the interacting residues of the different cystatin-A structures. The N-
terminal is on the right and the C-terminal-most loop is on the left. The big conformational
changes upon binding are more clearly visible then on the previous figure. Especially the
C-terminal-most loop and the N-terminal is completely different between the monomeric and
complex structures. Small differences are also visible between the cathepsin-H(1NB5) and
the cathepsin-B(3K9M) complex structures. These differences are mostly restricted to side-
chain conformational changes and models of one based on the other could be fairly accurate.
The biggest difference between the backbone conformations of the two complex structures is
just above the C-terminal-most loop (visible in the top-left) where the backbones differ and
the side-chains point in opposite directions.
Table 3.5 shows the RMSD between the different experimental structures of cystatin-B. The
biggest difference is between the monomeric structure and the complex structures. There is
also a significant difference between the conformations of the two complex structures.
For modelling, using monomeric structures as templates for complex models would lead to
significant errors. Using templates from complex structures where the protease is of the other
sub-family than in the target may introduce slight errors but should achieve good overall
accuracy.
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Figure 3.10 – Two structures of ovocystatin (1CEW, 1YVB) were superimposed and shown in the
ribbon representation. The side-chains of the residues that interact with the protease are shown in
red with their side-chains shown in line presentation.
3.5.3 Type II cystatins
Ovocystatin was chosen to represent this subfamily as it is the only member of the family to
have been solved in complex with a protease that also has a monomeric structure available.
Unfortunately there is no complex structure with a cathepsin-B like protease. The structures
used for the comparison can be viewed in Table 3.1.
Figure 3.10 shows a global overview of the ovocystatin structures. There is substantial flexi-
bility in the loops, at the end of the molecule, furthest away from the binding site (visible at
the top of the figure). The tryptophan residue, that is characteristic of the type II cystatins, is
clearly visible at the bottom-left of the picture. The side-chain points away from the core of
the cystatin, even in the monomeric form. In the monomeric crystal structure the N-terminal
was not resolved. Many studies have indicated that the N-terminal increases the binding affin-
ity and that truncation of the N-terminal reduces the affinity significantly Hall et al. (1995).
When binding to a protease the N-terminal becomes anchored and static, in the monomer
it is mobile. The other two loops show similar conformations between the monomeric and
complexed form. Using the monomeric structure as template for complex models would lead
to incorrect modelling of the N-terminal, a very important part of the interaction.
Figure 3.11 shows the interacting residues of ovocystatin. Differences are visible in the C-
terminal most loop (on the left). The orientation of the residues are very similar but they
show translational movement relative to each other. The middle loop is very similar but does
show some variation in side-chain conformations. The main difference in the N-terminal is
the number of residues visible in the experimental structures. Three residues are missing in
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Figure 3.11 – The interacting residues ovocystatin in 1CEW(blue) and 1YVB(red) are shown in
line representation.
the monomeric structure. Given the importance of the N-terminal region of cystatins, the
modelling of complexes using monomeric templates should be avoided.
The RMSD between 1YVB and 1CEW is 2.724Å, and this does not include the unresolved
N-terminal region. This is a substantial amount of variation and backs up the findings of the
visual inspection. The variation leading to the high RMSD is mainly in the loops, away from
the interface. The variation in the interface area is much less.
The PDB structure 1A67 was also investigated. 1A67 is a monomeric NMR structure con-
taining ovocystatin. The various solution structures published under 1A67 is shown together
with the X-ray structure 1CEW in Figure 3.12. This gives an indication of the natural flex-
ibility of the protein and hence is relevant to the question of what accuracy can realistically
be expected of a model.
The NMR data shows that the β-sheet part of the molecule is stable. There is a lot of flexibility
in the loop area (visible at the top of the figure), away from the interacting site. There is a
significant difference in the distance between the α-helix and β-sheet when comparing the
NMR structures to the crystal structure (not visible in figure). Since the loop at the top is so
flexible, it follows that it cannot be correctly represented in a single PDB structure and thus
cannot be modelled accurately using a structure format where each atom is given a single
position like the PDB file format.
The NMR structures were superimposed on the first one and backbone RMSD then calculated
relative to the average coordinates using VMD
(Visual Molecular Dynamics http://www.ks.uiuc.edu/Research/vmd/). The results are shown
in table 3.6. They vary from 1.517Å to 2.790Å. This is indicative of the flexibility of the
monomeric protein in solution and reinforces the points made above.
3.6 Results and discussion: Chagasin-like inhibitors
Chagasin itself was chosen to present this family as there are plenty of complex structures and
a monomeric crystal structure available. The structures used for comparison are indicated in
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Figure 3.12 – Ovocystatin from 1CEW (crystal structure) in orange and from 1A67 (NMR solu-
tion structures) in red (interface) and blue.
Table 3.6 – Backbone RMSD in Åbetween NMR solution structures of 1A67 and their averaged
structure.
RMSD
1 1.517
2 2.054
3 2.117
4 2.139
5 2.790
6 2.417
7 2.512
8 2.258
9 2.100
10 2.450
11 1.728
12 1.877
13 1.756
14 1.634
15 2.384
16 2.156
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Figure 3.13 – Five structures of chagasin (3H7W, 2OUL, 3CBJ, 2NQD and 3E1Z) were superim-
posed and shown in ribbon representation in blue. Interface residues are shown in red with their
side-chains in line representation.
Table 3.1.
Figure 3.13 shows an overall view of the different chagasin structures. The middle binding
loop clearly has the most consistent conformation while there is substantial variation in the
outer loops. The body of the protein, away from the interface also show substantial variation.
In the loop on the right, the variation is due to side-chain as well as backbone conformational
change. The loop on the left(in red) shows little conformational change except in 3E1Z in
which a residue from that loops interacts with papain. That interaction with papain seems
to induce a conformational change not present in any of the other complexes, nor in the
monomer.
Figure 3.14 shows the interacting residues of the different chagasin structures. The big change
in 3E1Z relative to the others can be clearly seen on the far left. The pink aspartic acid residue
(number 99 in original 3E1Z numbering) is on its own, far away from the others. Overall
there does seem to be some variability in the whole interface region. It must be noted that
the flexibility of the protein influences the superpositioning of interface residues which could
exaggerate the apparent variation.
The RMSD values in Table 3.7 show the variation between the individual chagasin structures.
The variation between the monomer and the complexes is of the same order as between
the complexes themselves. This indicates little conformational change upon binding and
significant flexibility in all forms. The most unique chagasin conformation is that of the
complex with papain.
When modelling a chagasin complex, use of the monomeric conformation as template could
possibly lead to an accurate model but has no advantages over using a complex conformation.
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Figure 3.14 – The interacting residues if 2H7W(red), 2NQD(green), 2OUL(blue), 3CBJ(yellow)
and 3E1Z(pink) are shown in stick representation.
Table 3.7 – RMSD values of indicated chagasin structures.
2NQD 2OUL 3CBJ 3E1Z
2H7W 0.826 0.643 0.964 1.083
2NQD 0.531 0.733 1.127
2OUL 0.762 1.062
3CBJ 1.204
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Using the conformation from 3E1Z is not advised as it shows a unique interaction.
3.7 Conclusion
The goal of this chapter was to gather information relevant to modelling decisions from the
experimental structures and provide context to the rest of the project. Also, to provide an
idea of what can be viewed as an accurate model. This was done by comparing different
crystal structures of individual proteins to each other. A comparison like this is limited by
the availability of experimental structures. Ideally one would have experimental structures
of the bound and unbound forms of the same protein available. Having multiple complex
structures with different binding partners is also helpful. More experimental structures would
have been useful, especially of type II cystatins. An experimental structure of cathepsin-B
bound to ovocystatin would be very interesting.
The findings showed that papain and chagasin do not undergo conformational change upon
binding. However, in the cases of the cathepsin-B, cystatin-B and ovocystatin, conforma-
tional change were detected. As a result, the modelling of complexes using monomeric ex-
perimental structures should be avoided. Only in the case of cathepsin-L like proteases can
the use of templates derived from monomeric structures be beneficial. In the case of chagasin,
using the monomeric structure as a template is viable but does not offer any advantages over
using the complex structures. Unlike with cathepsin-L like proteases, there are chagasin-
like inhibitors with experimentally determined monomeric structures that do not also have an
experimental complex structure.
It was found that the accuracy of the experimental structures examined vary from about
0.38Å RMSD upwards. The mobility/flexibility of a protein has a big influence on the RMSD
value that should be viewed as accurate. The NMR structures differed remarkably from the
X-ray diffraction structures, showing that the experimental technique used to produce exper-
imental protein structures has a substantial impact on the structure produced. Hence, models
produced through the use of computer based structure prediction may be accurate, even if
they are not exactly the same as the experimental structures. In theory, the application of
computer modelling techniques may actually improve the accuracy of experimentally pro-
duced protein structures. In the case of X-ray diffraction, the structures do not represent
the actual protein structure under physiological conditions. With NMR, the problem is that
the technique does not uniquely describe the structure but rather an ensemble. Some of the
members of this ensemble may not actually occur in nature but are simply indistinguishable
from the native structure through the data recorded. In both cases, theoretical physics and
chemistry consideration could be used to improve the structure and these can only be applied
through the use of computers, due to the computationally intensive nature of the problem.
A major obstacle is that there is no way to confirm whether theoretical predictions that go
beyond the accuracy of experimental techniques is actually correct.
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Chapter 4
Construction and evaluation of test
models
4.1 Chapter overview
This chapter describes the high-throughput modelling, evaluation and analysis of the test set
as described in Section 2.3.2. The chapter starts with a discussion of the aim and motivation
for carrying out such an extensive evaluation of modelling results. The method followed is
then described. The results and discussion are then given in the form of a summary and an
analysis of the produced data. Specific questions are addressed by graphing and calculations
of statistical metrics. A conclusion is given at the end.
4.2 Aim and motivation
The work of this chapter addresses some of the questions posed in Section 2.2. It aims to
answer the question of how to best choose a template for the modelling of C1 protease com-
plexes from the many possibilities available. This is a very important question as the selection
of the correct template has a major influence on the accuracy of any homology model. The
chapter also addresses the question of whether hybrid templates can produce similar quality
models to simple templates. This can be seen as an extension of the previous question as
hybrid templates are simply a subset of available templates. The test set models, built in this
chapter, also gave the opportunity to evaluate the ability of the Rosetta energy function and
the DOPE Z-score to discriminate between models of varying accuracy. This is important
as these are often used to pick models out of large sets of potential models. The effect of
Rosetta all-atom energy minimization on model accuracy was also investigated. This was
done as Rosetta all-atom energy minimization was considered as a possible step to increase
model accuracy in the study set models. The energy-minimization step was considered, espe-
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cially in the light of the hybrid models, as it was thought they would be likely to suffer from
small, local irregularities.
4.3 Method
The aim of this chapter calls for the comparison of the accuracy of different models. To
compare different models there must be an objective measure of accuracy. To accomplish
such objective accuracy measurements this chapter is modelled on the CASP and Capri com-
petitions where models are built of targets with experimentally determined structures. The
models are then compared to the experimental structure using objective metrics to evaluate
the similarity between the models and the experimental structure. Since the experimental
structures are considered to be the correct structure, models that are more similar to them are
considered better than models that are less similar.
Target complexes were identified and obtained from the PDB. Models for these complexes
were built as if their structure were unknown. Many different templates were used to model
each target structure. All the models were then evaluated using objective similarity metrics
from the CASP and Capri projects. The results for the different templates were then compared
and examined.
In an effort to get more accurate energy estimations and to improve model accuracy, all the
models were subjected to intense, all atom, energy minimization using the Rosetta 3.1 relax
protocol. The same evaluation metrics as before was carried out as before.
Two scoring functions, the DOPE Z-score and Rosetta energy were also evaluated by com-
paring the accuracy of the models to their scores according to these functions. This was done
before and after the energy minimization step.
4.3.1 Targets selected
The PDB was searched for experimental structures of complexes between C1 proteases and
cystatins or chagasins. Nine such structures were identified (See Section 2.4.1). These struc-
tures can be viewed in Table 2.1. There is significant redundancy amongst the targets. There
are four structures of chagasin, three structures of papain, two structures of falcipain etc.
Such redundancy, while problematic in the sense of reducing variation in the sample and
effectively reducing the sample size, can also be useful in other respects where it allows com-
parison between different proteins where the binding partner stays the same. It must be kept
in mind when analyzing the results.
4.3.2 Models built
The details of model building is described in Chapter 2. The creation of the templates used for
modelling of the test models is described in Section 2.4.3. Self templates, simple templates
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and hybrid templates were all used. The templates used for use each respective target is
described in Section 2.4.4. The alignment of target and template sequences are described in
Section 2.4.2. The modelling protocol is described in Section 2.4.5.
4.3.3 Calculation of scoring functions
For each model produced the DOPE Z-score and Rosetta energy was calculated as described
in Section 2.4.6.
4.3.4 Evaluation metrics calculated
The models were compared to the experimental structures by calculating various evaluation
metrics. All of the evaluation metrics could also be called similarity metrics, as they quantify
structural similarity. Metrics were chosen from existing, published, metrics to represent both
the global accuracy of the complexes as well as the accuracy of the interface region. The
chosen metrics and short description of each is given below:
RMSD Standing for Root Mean Square Deviation, RMSD is the oldest and most widely
used similarity metric in structural proteomics. RMSD is a type of weighted average.
It is used in many disciplines. In structural proteomics it is a weighted average of the
distances between corresponding positions of atoms in two different structures. RMSD
upweights the larger distances. The first step is to calculate the distances for each atoms
from the one position to the next. These distances are then squared, and the mean of the
squares calculated. The square-root of that mean is the RMSD. The RMSD depends on
the relative positioning of the two structures relative to each other. In fact, this is often
used to superimpose two structures onto each other. The position that minimizes the
RMSD is used as the optimal superpositioning. RMSD can be calculated for a subset
of the atoms in the protein, the backbone atoms and α- carbon atoms are often used
as such subsets. In this project, backbone RMSD was used. The algorithm for using
RMSD to superimpose two protein structures were first described 1982 (McLachlan,
1982). Lower RMSD indicates a more accurate model. An RMSD of 0 indicates
perfect similarity.
GDT-ha The Global Distance Test, roughly speaking, is an indication of what fraction of
the two structures being compared is the same between the two structures. To calculate
the GDT score, the fractions of atoms that fall within specific cutoff distances from the
corresponding positions in the other structure is calculated. These fractions are then
combined to give a single score by taking their mean. There are two main variations
of GDT: GDT-ts and GDT-ha. GDT-ha uses the most stringent cutoff distances and
since the models built in this project are expected to be very accurate, based on the
high sequence similarity and structural conservation in the cysteine protease family, it
is an appropriate choice. The cutoff distances used for GDT-ha is 0.5Å, 1.0Å, 2.0Å and
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4.0Å (Zemla et al. , 1999). GDT scores are more robust than RMSD scores when it
comes to atoms far from their correct position. In the case of RMSD, just a few atoms
that are far away from their corresponding position in the other structure can lead to
very bad scores. In GDT, the question is rather how many atoms are wrong, rather than
how far are they off. GDT scores vary from 0 to 1 with 1 being perfectly similar and 0
being completely dissimilar.
i-RMSD Interface RMSD is the RMSD as described above, using only the backbone atoms
of residues that fall in the interface of the protein complex. For the purpose of calculat-
ing i-RMSD, interface residues are defined as those residues with at least 1 atom within
10Å of an atom of the other protein in the complex. The interface residues are defined
by the conformation of the target molecule, in this case, the experimental structures.
The purpose of the i-RMSD score is to measure only the accuracy of the interface re-
gion, not the whole complex (Méndez et al. , 2003). Like with RMSD, i-RMSD must
be bigger than 0 and lower values indicate higher similarity.
F-nat and F-non-nat Specific residue-residue contacts is a very important aspect of struc-
tural predictions of complexes. This information can be used for the intelligent plan-
ning of mutagenic experiments. To measure the accuracy of residue-residue contact
prediction, two complimentary metrics are used. These are the fraction of native con-
tacts (F-nat) and the fraction of non-native contacts (F-non-nat). The fraction of native
contacts is the fraction of contacts in the experimental structure that are also present in
the model structure. The fraction of non-native contacts is the fraction of all contacts
in the model that are not present in the experimental structure. The fraction of native
contacts is analogous to sensitivity and the fraction of non-native contacts is analogous
to the false-positive rate in two-class predictions. For the purposes of these metrics,
two residues are considered to be in contact if they have one or more atoms within
5Å of each other (Méndez et al. , 2003). Both F-nat and F-non-nat vary from 0 to 1.
Higher F-nat values and lower F-non-nat values indicate more accurate models.
To carry out the calculations, some custom software was used in combination with pub-
licly available software. For calculation of RMSD, the program ProFit (Martin, A.C.R. and
Porter, C.T., www.bioinf.org.uk/software/profit/) was used. GDT-ha was calculated with the
program TMscore (http://zhanglab.ccmb.med.umich.edu/TM-score/ ) which calculates GDT-
ha in addition to several other metrics. ProFit was also used for i-RMSD, after identifying
the correct interface residues using custom software written in python. F-nat and F-non-nat
were calculated using custom software written in python.
4.3.5 Energy minimization carried out
To investigate the effect of Rosetta energy minimization on model accuracy, all-atom energy
minimizations was carried as described in section in Section 2.4.7 on all of the models and
the same evaluation metrics were calculated.
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4.4 Results and discussion
An analysis of the results are given below. All models with associated scores and metrics
can be obtained from the website accompanying this thesis at www.rubi.ru.ac.za/cpmdb. The
results and analysis given below aim to answer specific questions and is not an exhaustive
presentation of all data produced (such a presentation is not feasible).
In all the figures of this chapter, the color black is used for self models, red for simple mod-
els and blue for hybrid models. The color-key is shown in Figure 4.1 but left out of other
figures as the same color scheme is used throughout. Graphs were created using the statistics
program R (R-project.org).
4.4.1 General model accuracy
Before we directly compare the models to each other, it is instructive to get an idea of the
general model accuracy. Table 4.1 and 4.2 shows the median RMSD of every modelgroup. It
has sub-tables for each of the target complexes. Each cell represents a unique template for the
target of the sub-table. The source of the protease coordinates for the template are shown on
the left and the source of the inhibitor coordinates are shown at the top. The median RMSD of
the modelgroup based on the self-templates are shown at the top of each sub-table. Averages
are shown for each row and column with the overall average in the bottom right. RMSD was
chosen as it is the most often used metric.
These tables provide a useful overview of the results. Looking at the self models we see
that all of the self models have median RMSD values below 0.35Å which is roughly equiv-
alent to X-ray diffraction structure accuracy. This shows that under ideal circumstances, the
modelling protocol does not introduce a substantial amount of error.
The best result of the non-self models (simple and hybrid models) is for 1STF based on
H:3E1Z-P:1NB5-I (see Section 2.4.3 for an explanation of this notation), with a median
RMSD of 0.76Å. Second best, for the same target and with almost the same score of 0.77Å is
the modelgroup based on the H:3IMA-P:1NB5. The accuracy can be explained by the very
high similarity between the cystatin-B structure of 1STF and the cystatin-A structure of 1NB5
as well the near identical conformations of all the papain experimental structures (Figure 3.2).
The templates using the same protease sources but with cystatin-A, taken from 3K9M (with
cathepsin-B as protease), score slightly worse with scores of 0.85Åand 0.87Å. The cost in
accuracy in taking an inhibitor from a complex with cathepsin-B instead of from a com-
plex with cathepsin-H (which is cathepsin-L like as papain) was thus only 0.10Å. 2OUL was
also modelled very well, using H:1YVB-P:3CBJ, with an RMSD of 0.77Å. This is a case of
having both protease and inhibitor available in alternative experimental structures.
The least accurate modelgroup was that targeting 3K9M based on H:2OUL-P:1YVB-I and
achieved a median RMSD of 11.45Å. The cause of this inaccuracy is very clearly a case
of modelling cathepsin-B based on an cathepsin-L like template, resulting in the incorrect
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Table 4.1 – Median RMSD values (Å) of modelgroups in the evaluation set for cystatin containing
targets. The PDB ID of each target is shown in the upper left corner, inhibitor templates in the
top row and protease templates on the left. Averages are shown for each row and column and the
overall average shown in the bottom left corner. Median RMSD for the self-template modelgroups
are shown at the top.
1NB5 Self: 0.18 1STF Self: 0.28
1STF 1YVB 3IMA 3K9M Avg 1NB5 1YVB 3IMA 3K9M Avg
1STF 2.10 4.78 4.12 2.10 3.27 1NB5 1.67 5.05 4.00 1.72 3.11
1YVB 2.12 4.52 4.04 2.06 3.18 1YVB 1.97 5.02 4.12 1.99 3.28
2NQD 1.40 5.48 3.97 1.39 3.06 2NQD 1.48 4.71 3.87 1.54 2.90
2OUL 2.03 5.09 4.03 2.05 3.30 2OUL 2.01 5.22 4.12 2.05 3.35
3CBJ 3.70 6.60 5.30 3.65 4.81 3CBJ 3.30 6.14 4.92 3.28 4.41
3E1Z 2.05 5.17 4.13 2.05 3.35 3E1Z 0.76 4.20 3.68 0.85 2.37
3IMA 1.95 4.80 4.16 2.02 3.23 3IMA 0.77 4.72 3.74 0.87 2.52
3K9M 3.81 6.27 5.31 3.83 4.80 3K9M 3.57 6.23 5.04 3.55 4.60
Avg 2.40 5.34 4.38 2.39 3.63 Avg 1.94 5.16 4.19 1.98 3.32
1YVB Self: 0.29 3IMA Self: 0.18
1NB5 1STF 3IMA 3K9M Avg 1NB5 1STF 1YVB 3K9M Avg
1NB5 8.75 9.59 8.50 9.28 9.03 1NB5 2.17 2.24 2.14 2.41 2.24
1STF 9.03 8.35 7.58 8.82 8.44 1STF 1.61 1.68 1.48 1.85 1.65
2NQD 8.69 8.40 8.40 9.67 8.79 1YVB 2.49 2.56 2.42 2.75 2.55
2OUL 5.23 5.15 5.32 6.59 5.57 2NQD 2.05 2.13 2.05 2.34 2.14
3CBJ 8.52 8.82 7.93 9.41 8.67 2OUL 2.60 2.59 2.44 2.72 2.59
3E1Z 8.28 8.25 7.52 8.37 8.11 3CBJ 3.65 3.61 3.57 3.79 3.65
3IMA 9.19 8.32 8.87 9.08 8.86 3E1Z 1.59 1.65 1.51 1.86 1.65
3K9M 8.85 8.49 6.97 9.11 8.36 3K9M 3.94 3.88 3.77 4.00 3.90
Avg 8.32 8.17 7.64 8.79 8.23 Avg 2.51 2.54 2.42 2.71 2.55
3K9M Self: 0.23
1NB5 1STF 1YVB 3IMA Avg
1NB5 8.86 10.10 8.47 10.40 9.46
1STF 9.78 7.65 11.41 10.83 9.92
1YVB 10.30 8.80 10.65 11.18 10.23
2NQD 9.18 9.32 10.20 11.04 9.93
2OUL 9.29 9.51 11.45 10.78 10.26
3CBJ 2.09 2.12 4.95 3.81 3.24
3E1Z 9.39 10.11 10.55 7.99 9.51
3IMA 8.52 7.71 10.82 10.41 9.37
Avg 8.43 8.16 9.81 9.55 8.99
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Table 4.2 – Median RMSD values (Å) of modelgroups in the evaluation set for chagasin con-
taining targets. The PDB ID of each target is shown in the upper left corner, inhibitor templates
in the top row and protease templates on the left. Averages are shown for each row and column
and the overall average shown in the bottom left corner. Median RMSD for the self-template
modelgroups are shown at the top.
2NQD Self: 0.172 2OUL Self: 0.34
2OUL 3CBJ 3E1Z Avg 2NQD 3CBJ 3E1Z Avg
1NB5 1.51 1.44 1.73 1.56 1NB5 6.09 5.67 6.21 5.99
1STF 1.90 1.84 2.03 1.92 1STF 5.89 6.67 5.64 6.07
1YVB 2.07 1.97 2.25 2.10 1YVB 1.05 0.77 0.83 0.88
2OUL 2.15 2.02 2.26 2.14 2NQD 5.98 6.01 5.47 5.82
3CBJ 3.25 3.21 3.28 3.25 3CBJ 5.99 6.22 5.10 6.07
3E1Z 1.89 1.87 1.95 1.91 3E1Z 6.46 5.96 7.02 6.48
3IMA 1.85 1.83 2.17 1.95 3IMA 6.84 6.60 6.61 6.68
3K9M 3.45 3.41 3.55 3.47 3K9M 7.05 6.40 7.27 6.91
Avg 2.26 2.20 2.40 2.29 Avg 5.669 5.54 5.63 5.61
3CBJ Self: 0.20 3E1Z Self: 0.23
2NQD 2OUL 3E1Z Avg 2NQD 2OUL 3CBJ Avg
1NB5 8.35 8.26 9.21 8.61 1NB5 1.90 1.71 1.83 1.81
1STF 8.56 8.12 9.45 8.71 1STF 1.32 0.88 1.08 1.09
1YVB 8.97 9.06 9.08 9.04 1YVB 2.17 2.02 2.07 2.09
2NQD 7.87 8.15 8.19 8.07 2NQD 1.76 1.52 1.64 1.64
2OUL 9.04 8.99 9.10 9.04 2OUL 2.19 2.00 2.07 2.09
3E1Z 7.58 7.57 9.75 8.30 3CBJ 3.47 3.25 3.28 3.33
3IMA 9.27 7.37 9.46 8.70 3IMA 1.44 0.88 1.04 1.12
3K9M 2.29 2.22 2.29 2.27 3K9M 3.75 3.57 3.53 3.61
Avg 7.74 7.47 8.32 7.84 Avg 2.25 1.98 2.07 2.01
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modelling of the occluding loop; in addition, the modelling of a type I (cystatin-A) based
on a type II cystatin (ovocystatin) leads to the template-free modelling of the C-terminal
extension.
Many interesting deductions can be made purely by looking at the values in the tables. For
example, by looking at the results for models of 1YVB (falcipain-2 and ovocystatin) it may
not be immediately clear if the protease or the inhibitor are the main sources of error. How-
ever, by comparing the results to models targeting 2OUL we can conclude that the error is
mainly present in the inhibitor. This is because the excellent models of 2OUL based on the
1YVB protease (RMSD as low as 0.77Å) shows that the 1YVB and 2OUL proteases are very
much alike, yet even the best modelgroups of 1YVB, based on the 2OUL protease, have a
relatively high median RMSD, at 5.32Å. The source of the error therefore is clearly the in-
hibitor and most likely results from the template-free modelling of the insert on side of the
molecule opposite the interaction site. This region is absent in all the other cystatin structures,
including tarocystatin, the only other type II cystatin in the template set (Figure 3.7).
To further summarize the general model accuracy, the distributions of the RMSD, GDT-ha, i-
RMSD, F-nat and F-non-nat, for all models built in the test set, is shown in Figure 4.1. Since
F-nat and F-non-nat are closely related metrics, they are shown together on a scatterplot
instead of individually on a histogram like the other metrics.
The models cover a large range of accuracy. The RMSD and i-RMSD scores go up to12Å.
The i-RMSD scores are mostly clustered around 1.5Å with a long tail to the right. The RMSD
scores show a more flat distribution with a peak around 2.5Å. The GDT-ha scores vary from
0.35 to 1. F-nat varies from 0.4 to 1 and F-non-nat from 0 to 0.5.
The i-RMSD results show that the interface region of the proteins are generally more reliably
modelled than the global protein structures. The main contributor to large i-RMSD values is
the template free modelling of the cathepsin-B occluding loop when using cathepsin-L like
templates. Other factors include the modelling of cathepsin-L like models using cathepsin-
B and the modelling of type I cystatins using type II cystatin templates. If these 3 factors
are avoided, then all models have i-RMSD below 2.5Å. Global RMSD is affected by the
same factors, but additionally by the template free modelling of the nose and arm regions
in falcipain-2 and the template free modelling of the loop region in ovocystatin on the non-
interface side of the molecule.
The GDT-ha results give an indication of the side-chain accuracy and the self models are
clearly separated from the other models. Some hybrid models were built using identical
proteins to the target complex for both the protease and inhibitor. Such models give RMSD
results close to self models but their GDT-ha scores are clearly separated from the self models.
This indicates that errors are mainly associated with the side-chains.
In the case of F-nat and F-non-nat there is also a very clear separation of self models and
other models. As with GDT-ha this is likely due to side-chain sensitivity.
In all the metrics, the hybrid and simple models show similar distributions.
It is informative to get an idea of the variation in model quality within the modelgroups. To
summarize this, Figure 4.2 shows a scatterplot of the standard deviation of the RMSD, of
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Figure 4.1 – Distribution of major evaluation metrics for all test set models.
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Figure 4.2 – Standard deviation of RMSD values within a modelgroup as a function of the mean
RMSD of that modelgroup.
the models within each modelgroup, as a function of the mean RMSD of that modelgroup.
The result is very interesting. There is a clear and sharp increase in model variation starting
from about 4Å upwards. This is a comment on the method used to produce the models and
suggests that the program correctly recognizes accurate conformations and does not change
them significantly. In the presence of uncertainty or low confidence, such as the presence of a
loop, the program introduces more variation in an attempt to find a more accurate conforma-
tion. The variation between the models produced is thus an indication of the accuracy of the
models. However, this correlation is by proxy and there should be better ways to estimate the
accuracy of the models through examination of sequence similarity. In addition, the variation
of the models only places them in one of two categories of having RMSD greater or smaller
than 4Å. It is still very interesting to see the shape of the graph. It is not clear why there is
such a sharp increase instead of a more gradual rise.
4.4.2 Direct comparison of simple and hybrid templates
The act of creating hybrid templates (as described in Section 2.4.3) could potentially intro-
duce irregularities into the templates and these could carry over into the models. To test
whether this was the case, a subset of the test set, in which the model and hybrid templates
had the same distribution of sequences similarity to the targets, was analyzed. The major sim-
ilarity metrics were directly compared to each other using the Mann-Whitney U-test (Mann
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Figure 4.3 – Subset of test set used for the direct comparison between simple models and hybrid
models, only structures containing cystatin were considered.
& Whitney, 1947).
Only complexes with cystatin inhibitors and only proteases that are from crystal structures
with cystatin were included in the subset (Figure 4.3). This insures identical sequence sim-
ilarity distributions across both classes of models. While this causes a big decrease in total
number of models, only 2 test set proteins are completely excluded from the set. These are
chagasin and cathepsin-L. To see why this selection ensures identical similarity distributions,
refer to Figure 4.3. The exclusion of chagasin limits the target complexes to those containing
cystatin. That leaves five targets, each modelled using four simple templates and twelve hy-
brid templates obtained from the other four targets. Thus, for modelling the target protease,
four template proteases are available. Each of the template proteases is used once in a simple
template and three times in a hybrid template. This fixed ratio of 1:3 ensures that the distri-
butions are the same. For a single target, every time a specific protease is used in a simple
template it is used three times in a hybrid template. A similar argument can be made for
the inhibitors. Thus, for each target, the distribution of sequences used is exactly the same
between the the simple templates and hybrids. Since all targets have the same number of
templates, this equality is preserved when pooling them all together to give the comparison
subset.
The Mann-Whitney U-test allows the comparison of unequal samples with non-normal dis-
tributions. It uses a statistic based on the ordering of results from two sets to calculate the
probability of encountering the observed difference between two sets as a result of random
sampling error. This probability is called the P-value. The P-value also depends on what
alternative hypothesis is used. The alternative hypothesis is the alternative to the null hy-
pothesis. The null hypothesis is that the two samples are the same, in terms of the measured
quality. The most common alternative hypothesis is simply that the two samples differ. A
one-sided alternative hypothesis assumes that any difference between the two sets can only
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be in one direction. In other words it assumes that the measurements of set A may be larger
than the those of set B, but the measurements of set B cannot be larger than those of set
A. The alternative hypothesis used, in the present comparison, was that the simple models
are more accurate than the hybrid models. Thus, a one-sided alternative hypothesis was used.
This was done as there is no reason to suspect that a hybrid model would be better than a sim-
ple model, given the same sequence relationships between the template and target proteins.
Figure 4.4 shows the distributions of the major evaluation metrics, for the representative set
only, along with the differences between the means of the sets and the P-values resultant from
the Mann-Whitney tests.
The results support the null-hypothesis - that there is is no significant difference between the
simple and hybrid models in terms of the major evaluation metrics. The difference between
the means of the metrics are very small in any case. The metric with the most significant
difference is F-non-nat with a P-value of 0.13 and a difference of 0.0095 between the means.
It is interesting that the i-RMSD and RMSD scores are actually lower (by an insignificant
amount) in the hybrid models than in the simple models. The GDT-ha score for the hybrids
is smaller by an insignificant amount.(P-value of 0.31)
The result is quite interesting as it shows that hybrid models are of the same quality as simple
models. Irregularities in the structure, produced in the hybrid construction process, are either
insignificantly small or are overcame by the modelling protocol. On the practical side, the
result means that there is no loss in accuracy when using hybrid templates. When selecting
templates for the modelling of further complexes, no compromise between the inhibitor and
protease is necessary. The best template for the protease and the best template for the inhibitor
can both be used without introducing errors.
4.4.3 Examination of relation between model accuracy and sequence
identity and coverage
This section investigates the relationship of sequence identity and coverage with model accu-
racy.
Sequence identity is the percentage of amino acids between two sequences that are conserved.
Positions in the sequence, where either sequence has a gap in the alignment, are ignored.
Sequence identity is a measure of the evolutionary distance between two proteins. The higher
the identity, the more recent is the common ancestor of the sequences. There is a correlation
between sequence identity and structural similarity (Chothia & Lesk, 1986). Since structural
similarity between the target and template proteins is the main factor influencing the accuracy
of a homology model, sequence identity is a good indication of the accuracy that can be
expected of a model.
Sequence coverage is the percentage of amino acids in a sequence which are not aligned to
gaps. The sequence coverage is thus a measure of the amount of ”gaps” in the other sequence.
In the context of homology modelling, it can be used as a measurement of how much template
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Figure 4.4 – Comparison of major evaluation metrics between simple and hybrid models of a
subset of the test set. Distributions, differences between means, and Mann-Whitney U-test P-
values of the major evaluation metrics are shown. The difference in means were calculates by
subtracting the means of the simple models from the means of the hybrid models. The graphs
show histograms with a normalized frequency on the y-axis and the values of the evaluation
metric itself on the x-axis.
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free modelling has to be done for a target protein. One can say that a model was built at 80%
coverage, meaning that 80% of amino acids of the target protein was aligned to a template
structure. Since template free modelling is a major source of errors in structural models,
the sequence coverage is an important measurement that is correlated with the accuracy of
homology models.
To elucidate the relationship between sequence identity and coverage with model accuracy,
RMSD and i-RMSD were investigated. RMSD serves as a measure of global accuracy while
i-RMSD is a measure of the interface accuracy.
Figure 4.5 shows the median RMSD of the test set models as functions of inhibitor identity,
protease identity, inhibitor coverage and protease coverage respectively. Each target complex
is shown as a separate data series. Where inhibitor identity or coverage is shown on the x-
axis, the RMSD was averaged over the various proteases used. Similarly, the average over
the various inhibitors was taken where protease identity or coverage is shown on the x-axis.
In this way, the influence of inhibitor and protease error on the RMSD can be separated. The
slope of the lines carry the information in these graphs. The absolute value of the series is
unimportant as it is influenced by the contribution of the other complex component, not the
one being investigated.
It is interesting to see that increasing inhibitor sequence identity from 50% to 100% does not
seem to improve the model RMSD. This shows that the structure of the inhibitor (in this case
cystatin) is still highly conserved at the level of 50% sequence identity. In the case of protease
sequence identity, it can be seen that the relation is not consistent and depends on the specific
case under consideration. The trend is always that higher sequence identity leads to lower
RMSD values, however, by how much it is lowered, depends on the specific case. There is
some unexpected results when looking at the sequence coverage of the inhibitors. There is
clearly an increase in RMSD (decrease in accuracy) associated with an increase in coverage in
the section of the graph between 80% and 90% coverage. The targets visible there are all type
I cystatins and the two inhibitor templates are 1YVB - ovocystatin and 3IMA - tarocystatin.
The coverage provided by ovocystatin is higher, although its structure is farther from that of
the type I cystatins. The protease show a much clearer and more consistent downward trend
with regards to sequence coverage.
Figure 4.6 was constructed in exactly the same way as figure 4.5 except that it shows i-
RMSD instead of normal RMSD. The results, again, are interesting. The correlation between
i-RMSD and inhibitor coverage is very strong. It is also surprising that some of the best
models in terms of i-RMSD was built at the lowest levels of coverage. This is explained by
the fact that the gaps do not occur in the interacting region. For the proteases it seems that
the strongest correlation is with sequence identity.
Overall, the results support the theoretical position that higher sequence identity and higher
sequence coverage is correlated with more accurate models. However, the results also show
there is no one-to-one relationship between these metrics and accuracy. Depending on the
specific case, identity or coverage may be more important and the impact may vary. Structural
knowledge of the families serving as templates and targets is useful in interpreting the results
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Figure 4.5 – Plots showing the relationship between RMSD, sequence identity and sequence
coverage for each of the 9 targets.
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Figure 4.6 – Plots showing the relationship between i-RMSD, sequence identity and sequence
coverage for each of the 9 targets.
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and selecting templates.
4.4.4 Examination of relationship between scoring functions and model
accuracy
An often used method for increasing model accuracy is to build many models and then select
the best one to use further. A scoring function, in the protein modelling context, can be used
to refer to any mathematical function that has as input a protein structure and outputs a value
that aims to be an indication of the accuracy of the model. Physical energy functions and
statistical potentials are often employed as scoring functions, to select the best models from
a set of potential models. Two scoring functions, the Rosetta energy function and the DOPE
Z-score were tested for their ability to identify accurate models. The scoring function values
were calculated for all the the test models and compared to the actual accuracy of the models,
as measured using RMSD, to evaluate their performance.
Figure 4.7 shows a positive correlation between the RMSD and Rosetta energy. A lower
Rosetta energy typically corresponds to a lower RMSD value and in all cases the best(lowest)
scoring model is one of the most accurate models. The correlation is not very strong. For a
given energy score, the corresponding RMSD value can vary quite substantially. Some results
seem to defy the correlation completely. Specifically, some models of complex 1STF have
very low energy scores despite having double the RMSD of other models with much higher
energy values. In conclusion, the Rosetta energy does show a clear, positive, correlation with
RMSD and a low energy model is thus likely to be more accurate than a high energy model.
Figure 4.8 shows a similar positive correlation between the DOPE Z-score and RMSD values.
Inspection indicates fewer anomalous scores than with Rosetta energy. The models for 1STF
still contains a subset of models that are scored too low(with respect to RMSD) but they are,
correctly, scored significantly worse than the best cluster, unlike with the Rosetta energy. In
other cases like 1NB5 and 3K9M, DOPE Z-score also show better performance than Rosetta
energy as the best models are scored lower than the others.
Both scoring functions clearly show the ability to make better than random selections out of a
set of models built on different templates, with DOPE Z-score showing slightly better perfor-
mance. The next question is if they are able to identify the best model within a modelgroup.
This is very important. The reason for building multiple models, using the same template, is
that the chance of building an accurate model is increased through multiple attempts. If the
most accurate model cannot be identified, it creates a situation where the researcher cannot
determine which model to use for further work and the benefit of building multiple models
is largely lost. In the best case scenario, the researcher can carry on research with the entire
ensemble of models, but this is currently not practical in most cases.
To evaluate the ability of the two scoring functions to identify the most accurate models in
a modelgroup, the score of each model, relative to the mean score of its modelgroup, was
plotted as a function of its RMSD, relative to the mean RMSD of its modelgroup. In other
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Figure 4.7 – Rosetta energy as a function of RMSD for all models in the test set. Each target
complex is shown in its own sub-graph.
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Figure 4.8 – DOPE Z-score as a function of RMSD for all models in the test set. Each target
complex is shown in its own sub-graph.
85
words, the shift in score relative to the modelgroup was plotted as a function of the shift in
RMSD relative to the modelgroup. If the scoring functions are successful, accurate models
(which have a lower RMSD than the mean RMSD of the modelgroup) should have scores
lower than the mean score for that modelgroup (in both Rosetta energy and DOPE Z-score,
lower scores correspond to more accurate models) and thus would appear on the bottom left
of the graph. Similarly, inaccurate models should appear on the top right of the graph. A
successful scoring function would thus result in positive correlation with the results forming
a trend from the bottom left to the top right.
In Figure 4.9, with the exception of the self models, no such trend is visible for either Rosetta
energy or DOPE Z-score. The Pearson Correlation coefficients also indicate that the scoring
functions fail with the simple and hybrid models. In contrast, it seems that both scoring
functions are actually able to detect the more accurate models amongst the self models. From
this result, it seems possible that the scoring functions are in fact able to identify the most
accurate models amongst already very accurate models and that this ability is hidden by the
less accurate models amongst the simple and hybrid models.
To examine whether the performance of the scoring functions varies according to the accuracy
of the model, the Pearson correlation coefficient between the scoring functions and RMSD
within each modelgroup was plotted as a function of the mean RMSD of that modelgroup. In
this case a positive correlation indicates good performance. The lines indicate the mean value
of the datapoints in 1Å bins. In other words, the line indicates the mean Pearson Correlation
coefficient achieved within a certain range of accuracy. The accuracy ranges used were 0.0Å -
1.0Å, 1.0Å - 2.0Å, 2.0Å - 3.0Å. etc.
Figure 4.10 supports the conclusion that the scoring functions are unable to distinguish be-
tween models within a modelgroup. For very accurate models (below 2Å) the results is in-
conclusive but even if there is a slight correlation between accurate models and good scores,
it is very weak. Overall, the deviations from zero show no pattern and are thus likely due
to random chance. The biggest deviations from zero occur where there are few data points,
making them unreliable. It is also better to look at the hybrid models as there are more data
points and thus higher confidence. In the case of the self models, the scoring functions defi-
nitely show the ability to correctly identify accurate models (better than random). A possible
explanation for this is that the scoring functions take the side-chains into account, while they
are not reflected in the RMSD scores. In the self models, the side-chains are more likely to
be correct and thus less likely to skew results of the scoring functions.
4.4.5 Examination of minimization results
4.4.5.1 Effect on accuracy
To examine the effect of the energy minimization on accuracy, the changes in the major eval-
uation metrics are shown in Figure 4.11 as a function of their value before the minimization.
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Figure 4.9 – The score of each model, minus the mean score of the modelgroup, is plotted against
the RMSD value of that model, minus the mean RMSD of the modelgroup. The numbers in the
corner of the graphs indicate the Pearson correlation coefficient between the scoring function and
RMSD in each case for self models, simple models and hybrid models.
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Figure 4.10 – The circles indicate the Pearson correlation coefficient between the indicated scor-
ing functions and RMSD within each modelgroup is shown as a function of the mean RMSD of
the modelgroup. The lines indicate the average value of each series over intervals of 1 Å.
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Figure 4.11 – Changes in evaluation metrics due to minimization is shown as a function of the
value before minimization.
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This was done as there was reasonable suspicion that the effect might be dependent on the
accuracy before minimization.
From the figure it is clear that minimization leads to a decrease in accuracy (in terms of
the evaluation functions) in models that are already very accurate. This is expected as any
change in a highly accurate model is likely to reduce the accuracy. It is noteworthy that
the loss in measured accuracy is only slightly larger than the variation between different
crystal structures of the same proteins. The minimization is thus not necessarily making the
model more different from the native protein structure, but different from the crystallized
conformation.
For the less accurate models, it seems that roughly the same number are improved as de-
graded. This is very impressive and could be very useful if improved models could be reliably
detected afterwords (without having the experimental structure available as it is here) so that
improvements can be retained while degradations are discarded. Unfortunately, according to
to findings of section 4.4.4, that is not possible.
GDT-ha seems to be reduced in the majority of cases. This is likely due to the already
accurate models and the sensitivity of GDT-ha to side-chain conformations. The fraction of
native contacts was improved almost universally while the fraction of non-native contacts
was worsened. This implies that the total number of contacts predicted for each model was
increased and the protease and inhibitor were brought into closer contact than before. The
i-RMSD scores worsened in the case of already low scores but there seems to be a trend
toward improvement for less accurate models.
4.4.5.2 Are the energy scores more accurate for the minimized models?
Since the scoring functions, especially the Rosetta energy, can be sensitive to small, local,
irregularities, it is possible that their performance would be better with minimized models in
which such irregularities should theoretically be removed. As before, the Pearson correlation
coefficient between the scoring functions and the RMSD values after minimization within
each modelgroup is shown as a function of the mean RMSD of that modelgroup. The lines
indicate the mean of the datapoints in each series in 1Å bins.
Figure 4.12 shows a very small, but real, improvement over Figure 4.10 for the DOPE Z-
score. The DOPE Z-score now clearly has a small but positive correlation as the mean cor-
relation coefficient is above 0 far more than below. This correlation is still very small and
selecting the top-scoring models will only provide a slight enrichment of accurate models in
the selection.
4.4.5.3 Examination of relation between the energy change during minimization with
the accuracy of the model
Since a good model should already have a low energy it should not, on average, improve as
much as a less accurate model. The change in the scoring functions are shown as a function
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Figure 4.12 – The circles indicate the Pearson correlation coefficient between the indicated scor-
ing functions and RMSD within each modelgroup is shown as a function of the mean RMSD
of the modelgroup after minimization. The lines indicate the average value of each series over
intervals of 1 Å.
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Figure 4.13 – Change in scoring functions as a function of the RMSD before minimization.
of the RMSD before minimization.
As expected, figure 4.13 shows that the worst models show the greatest improvement in score.
This trend flattens off for the DOPE Z-score, which is expected as it is a normalized Z-score.
A model that changes a lot during minimization is thus not as reliable as one that remains
stable. Since the variation in scoring functions is significantly bigger than the variation in
RMSD within a modelgroup, it is best to use the mean or median of the scoring function to
represent the group than to take the value from just one of the models.
4.5 Conclusion
1325 homology models of C1 protease complexes with known experimental structures were
built in order to investigate factors that can influence model accuracy. Various metrics were
calculated to assess the accuracy of each model. The RMSD ranged from 0.172Å to 11.45Å.
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In general, no significant difference between hybrid and single-template models, in terms of
the evaluation metrics investigated, was detected. As such, hybrid templates can be used for
modelling C1 complexes with cystatins whenever this enables more closely related proteins
to be used for the individual proteins. This means that when modelling such a complex, the
templates for the inhibitor and protease should be independently selected without regard as
to what experimental structure it comes form.
It was found that both sequence identity and sequence coverage are positively correlated with
accurate models. However, the correlation is not simple or linear.
The two scoring functions that were evaluated, the Rosetta energy function and the DOPE
Z-score, were able to discriminate between models from different templates but could not suc-
cessfully differentiate between models built on the same template. Overall, they performed
very similarly. DOPE Z-score performed better in a few cases.
Many of the less accurate models ( RMSD > 4Å) did show improvement after minimization
but these models could not be identified using the scoring functions. As such, the improve-
ments are not practically useful. It was confirmed that less accurate models showed larger
improvements in terms of their scoring functions as a result of minimization than more ac-
curate models. The RMSD scores of accurate models did not improve and were increased in
most cases.
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Chapter 5
Construction of novel models
5.1 Chapter overview
In this chapter, a high-throughput modelling pipeline was used to model 110 C1 protease
complexes. The chapter starts with the aim and motivation for building these particular mod-
els. The method used for modelling is then described and a list given of proteins included.
The template selection and scoring function results are then given and discussed in the re-
sults and discussion section while the models themselves are available on the website at
http://rubi.ru.ac.za/cpmdb. The chapter ends of with a short conclusion.
5.2 Aim and motivation
The aim of this chapter was to accurately model complexes that are of interest due to their
roles in research or disease. Cysteine proteases and inhibitors from human, malarial and
plant sources were selected. The human and malarial proteins are of interest since they are
important because of their role in human disease while the plant proteins, papain and taro-
cystatin, are of interest due to their roles in biotechnology and food-production. For the
sake of simplicity the models were constructed in an all against all fashion - combining all
proteases with all inhibitors.
These models can be used for further studies investigating the complexes. Because of the
large number of models, the use of statistics become possible and may enhance the knowledge
gained as opposed to just building models for one specific complex of interest.
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5.3 Method
5.3.1 Targets selected
The proteins selected for the study set is given in Table 5.1. Proteins were manually selected,
loosely based on their importance in research and their relevance to malaria. Experimental
value to the dataset were also considered. Providing diversity, providing experimental con-
trols, and having experimental data available were considered as adding experimental value to
the dataset. For example, kininogen-1 is not actually a cysteine-protease inhibitor, in spite of
the sequence similarity to cystatins, so including it in the dataset serves as a form of negative
control.
The selected proteases and inhibitors were combined in an all against all fashion to give the
complexes to be modelled. Some of these complexes do not occur naturally but were included
because it is more expedient to include them than trying to decide which have to be left out.
Apart from the extra computational time required to build them, their presence does no harm.
5.3.2 Template selection
Templates for modelling were selected from the template set described in Section 2.4.2 by
selecting templates for the protease and inhibitor independently from each other. For pro-
teases, sequence coverage was used as the criteria for selecting a template while sequence
identity was used for the inhibitors. The reason for the differentiation between the two is that
the inhibitor gaps are situated away from the active site and thus less important. Figure 4.5
and Figure 4.6 were also considered in making this decision. The establishment of a single
criteria to select templates greatly aided the automation of the modelling process.
5.3.3 Model building, energy minimization and calculation of scoring
functions
After templates were selected, the modelling procedure as described in Section 2.4 was fol-
lowed. This resulted in 5 models for each complex plus energy minimized versions of each
of those models, all with accompanying scoring function results.
5.4 Results and discussion
5.4.1 Template selection
The result of the template selection step is shown in Table 5.2. Sequence identity and cover-
age values are generally high. The lowest values are 12.3% and 87.7% respectively.
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Table 5.1 – Proteins selected for modelling in the study set.
Name Organism
Proteases
Cathepsin-B H. sapiens
Cathepsin-H H. sapiens
Cathepsin-L H. sapiens
Cathepsin-S H. sapiens
Falcipain-2 P. falciparum
Falcipain-2p P. falciparum
Falcipain-3 P. falciparum
Vivapain-2 P. vivax
Vivapain-3 P. vivax
Vivapain-4 P. vivax
Papain C. papaya
Inhibitors
Chagasin T. cruzi
Falstatin P. falciparum
Cystatin-A H. sapiens
Cystatin-B H. sapiens
Cystatin-C H. sapiens
Ovocystatin G. gallus
Taro-cystatin C. esculenta
Kininogen-1 H. sapiens
Kininogen-2 H. sapiens
Kininogen-3 H. sapiens
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Table 5.2 – Results of template selection of the study set proteins. The templates chosen for each
protein is indicated by its PDB ID and the sequence identity and sequence coverage are indicated
in percentages. The size of each protein is given by the number of amino acid residues.
Protein name Template Identity Coverage Protein size
Proteases
Cathepsin-B 3K9M 100.0 100.0 254
Cathepsin-H 1NB5 92.3 100.0 220
Cathepsin-L 2NQD 98.6 100.0 221
Cathepsin-S 2NQD 56.7 99.1 223
Falcipain-2 1YVB 100.0 100.0 241
Falcipain-2p 1YVB 95.9 100.0 241
Falcipain-3 1YVB 66.4 99.2 243
Vivapain-2 1YVB 62.2 99.2 243
Vivapain-3 1YVB 56.8 98.4 245
Vivapain-4 1YVB 54.6 99.6 242
Papain 3E1Z 100.0 100.0 212
Inhibitors
Chagasin 2OUL 100.0 98.1 109
Falstatin 2OUL 12.3 97.2 110
Cystatin-A 1NB5 100.0 100.0 98
Cystatin-B 1STF 98.0 100.0 98
Cystatin-C 1YVB 45.9 92.5 120
Ovocystatin 1YVB 100.0 100.0 111
Taro-cystatin 3IMA 100.0 93.4 91
Kininogen-1 1YVB 25.9 91.5 121
Kininogen-2 1YVB 20.6 87.7 126
Kininogen-3 1YVB 28.0 87.7 126
The experimental structure 1YVB is used for many different proteins. In the protease sec-
tion, it is used for all the Plasmodium proteins. Falcipain-2 is the only closely related protein
to these proteases available in the template structures and occurs in 1YVB and 2OUL. As
the two structures contain the same protein and hence have the same sequence identity and
coverage values, the choice was arbitrarily made by the program based on the order in which
they were originally entered into the program. In the case of the inhibitors, ovocystatin from
1YVB was justifiably used in many cases as it is one of only 2 type II cystatins with exper-
imental structures in the complex form (and tarocystatin lacks a certain feature as described
in Section 3.5.1).
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5.4.2 Scoring function results before minimization
Table 5.3 shows the scoring function results for all the complexes of the study set before
minimization. Overall, the scores are very favourable. All the DOPE Z-score values are
negative (lower DOPE Z-score values indicate more accurate models) with the highest one
being -0.219 for the complex with kininogen-3 and vivapain-4. The lowest value is -1.43
for the complex between cystatin-A and papain. The Rosetta energy values are all positive,
ranging from 3111.4 for the complex between falstatin and vivapain-3 down to 537.6 for
the complex between chagasin and cathepsin-L (lower Rosetta energy values indicate more
accurate models). As Rosetta energy is not normalized to protein size, comparisons between
different complexes should not be made.
5.4.3 Scoring function results after minimization
The scoring function results after minimization is shown in Table 5.4. All the Rosetta en-
ergy values are now negative and range from -827.6, for the complex between chagasin and
falcipain-2, to -612.9, for the complex between falstatin and cathepsin-L. DOPE Z-scores are
also much lower than before minimization and range from -1.78, for the complex between
cystatin-A and cathepsin-S, to - 0.814, for the complex between kininogen and VP-4.
5.5 Conclusion
Models of 110 unique complexes were built and evaluated using Rosetta energy and DOPE Z-
score. These models were built in the same context and using the same techniques as the test
set models and thus conclusions made regarding the test models can be extrapolated to these
models. The value of these models are thus increased compared to the average homology
model because of they can be compared to the models of the test set.
The models produced generally have very good DOPE Z-score and Rosetta energy values
which is consistent with accurate models. Considering the sequence identity and sequence
coverage at which most these models were built, it is likely that they are close to their native
structures. In the case of falstatin, the models are likely inaccurate as the sequence had large
segments removed to increase the sequence coverage to levels that made modelling possible.
These models represent accurate models of the respective complexes (excluding the falstatin
complexes) and can be used for further studies.
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Chapter 6
Creation of website
6.1 Chapter overview
This chapter discusses the website that accompanies this thesis. The reason for providing
the website is explained at the start of the chapter, more detail is provided on the technical
aspects of the development in the method section followed by a description of the website
in the results and discussion section. The chapter is finished off with a conclusion about the
website.
6.2 Aim and motivation
The project produced over a thousand models and a large amount of useful information about
the accuracy of the modelling process itself and the performance of two specific scoring
functions. Most of this data is useful in itself and can be analyzed further to gain insight
into the homology modelling process, the scoring functions examined and the relationships
between the different proteins. This information can only be analyzed electronically, due to
the nature and amount, and as such is more useful in an electronic format. To encourage
further use of the data it was decided to make it publicly available on a website. Such a
website was developed and called CPmDB (Cysteine Protease model DataBase). The aim of
the website is to provide a user-friendly interface to access the raw data.
6.3 Method
It was decided to use the Django framework to develop the website. Django is a rapid web-
development-framework written in the Python programming language that helps developers
to quickly create dynamic websites and enforces the use of good programming practices.
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Django uses the Model-Controller-Viewer paradigm to separate the different aspects of a
dynamic website into 3 distinct parts.
Model Responsible for storage and retrieval of raw data.
Controller Responsible for processing data and any complex operations that form part of
the website functionality.
Viewer Presentation of data in a suitable layout.
For the model layer a MySQL database is used to store the data. Django has its own database
interface to interact with the database. The reason why the original python modules that in-
teract with the project data could not be used directly, is that loading them takes too long.
The MySQL database allows Django to load only the required data, and improves the perfor-
mance of the website significantly by taking advantage of modern relational database tech-
nology. Python functions were written to load the data from the python modules, used in
the rest of the project, into the database. The database was loaded with all of the data and
molecular structures used in the rest of the project by running these functions.
The controller is a python module where certain functions are linked to specific URLs via
regular expressions (regular expressions are a common way to define patterns in character
sequences). These functions must return the formatted page that the user receives in his/her
browser. The functions and procedures of the controller performs any processing of data that
is necessary to generate the page requested by the user. While the controller can produce
the formatted page directly, it is more common and better programming practice to leave
formatting the viewer part of the program.
In Django, the viewer takes the form of a template language and python modules that facil-
itate the loading and rendering of templates. Templates are text files with special tags for
specifying parts of the page that can be changed. These parts have to be correctly specified
each time the template is used. It is the job of the controller to provide data to the viewer
so these fields in the template can be correctly populated. The idea is to provide all the for-
matting and layout information in invariable part of the template. Some logic and control
functions can be performed in the template as well to accommodate cases where is uncer-
tainty about the nature of the data that needs to be displayed. The logic and control functions
allow the template to adapt to the data it receives from the controller.
6.4 Results and discussion
6.4.1 General
The website was successfully completed and is available at http://rubi.ru.ac.za/cpmdb.
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Figure 6.1 shows a screenshot of the homepage. A navigation panel on the right provides
quick access to the different sections. Content is shown in the main display window which
fills up most of the space.
The content is divided into two main sections, the download section and browsing section.
The download section allows users to download bulk data pertaining to the project. It has
separate pages for the alignment, test set data and study set data. The browsing section allows
users to explore the data by following links through a hierarchy, representing the project. For
alignments, the browsing section and download section is the same.
6.4.2 Alignment section
The alignment section consists of page showing a list of the alignments used and a page for
each of the alignments. The user accesses the individual alignment pages by clicking the
items in the list. On the individual alignment page a list of all the proteins in the alignment
is given. The alignment itself can be browsed using the Jalview (http://www.jalview.org/)
application. The alignment can also be downloaded in fasta format. These pages allow both a
detailed view of the individual alignments as well as the ability to download the information.
The alignment link in the download section and browsing section points to the same page.
6.4.3 Download section
The download section provides filters with which to select subsets of the data to download.
Such filters are given for the study set and test separately. The filters act together in such
a fashion that the complex must satisfy the condition of all the filters to be included in the
results. A choice is given whether the user wants to download median values for each mod-
elgroup or the individual results of each model. Upon setting the filters, the user is presented
with a list of complexes that satisfy the criteria. The user can then choose to download the in-
formation for the selected complexes or to change the filter settings. When the user chooses
to download the results, a CSV (comma separated values) file is generated and sent to the
user. The CSV file can be be opened in most spreadsheet programs.
6.4.4 Browsing section
The browsing section allows the user to peruse the data. In addition to the alignment section
described already there are sections for the test set and study set. The link for each set is
organized in a different way. The test set uses a hierarchy with two levels. The highest level
is target complex and the second is modelgroup. The study set uses only one level which is
modelgroup. In both study set and test set, a page is available for each modelgroup on which
all the data for each model and the structure files of each model is available.
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6.5 Conclusion
The website was successfully constructed and all the data produced in the project is available
there. It is hoped that other researchers will make use of the data, the proper analysis of which
was beyond the scope of this project. The interface is relatively simple. Initially, access to
the website is be restricted by requiring a username and password to view the content. This
is a temporary restriction that will be lifted as soon as documents, currently in writing, can
be published. Access to data is an important cornerstone of science in general and especially
bioinformatics. It is hoped that giving free and unlimited access to research data will become
the standard practice in future.
105
Chapter 7
Conclusion
7.1 Chapter Overview
In this project, the high-throughput modelling of protein complexes containing C1 cysteine
proteases and protein inhibitors were studied. To this end the following actions were carried
out:
1. The structural variation between the protein sub-families, and conformational changes
upon complex formation were examined.
2. Test models were built, to evaluate modelling accuracy, and accuracy metrics for these
models were calculated.
3. Hybrid templates were introduced and a comparison between hybrid models, and sim-
ple models were carried out.
4. The effect of energy minimization using Rosetta all-atom energy minimization was
examined.
5. Two metrics, the Rosetta Energy and the DOPE Z-score, were examined for their ability
to discriminate between models of varying accuracy.
6. Several complexes of unknown structure were modelled using information from the
preceding studies to select the best templates.
7. A website was created for distribution of data pertaining to the project.
This chapter tries to make conclusions based on the results of these actions as presented in the
previous chapters. Some conclusions draw from more than one of the chapters and so they are
not ordered according to chapter. A section is given for each logically separate conclusion,
followed by a closing paragraph.
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7.2 Conformational change can occur during complex for-
mation between C1 proteases and protein inhibitors
The results of chapter 3 showed that some of the proteins examined undergo conformational
change upon binding. The most significant change is arguably the movement of the cathepsin-
B occluding loop to accommodate the inhibitors in the active site cleft. Cathepsin-B has a
clearly favoured conformation for the occluding loop as is shown by the structure 1GMY
where all three conformations of monomeric cathepsin-B show the same conformation for
the occluding loop. Upon complex formation the occluding loop is pushed away from this
favoured position.
Both cystatin subfamilies also undergo conformational changes upon binding. Most notably,
the N-terminal region binds to the protease in a stable conformation while being highly mo-
bile in the monomeric state. Differences between the cystatin-A conformations in 1NB5 (with
cathepsin-H) and 3K9M (with cathepsin-B) show that cystatin-A adapts its conformation to
fit the protease its binding to.
Chagasin shows more similar conformations between the bound and monomeric form than
cystatin. There is however one interesting structure where chagasin shows an interaction
with papain not present in any of the other complexes where chagasin undergoes a slight
conformational change (3E1Z).
Papain does not undergo conformational change upon binding to cystatin or chagasin, it
shows almost perfect similarity between 4 different crystal structures which includes 3 com-
plexes and one monomeric structure.
The main implication here with regards to the modelling of complexes is that, with the ex-
ception of cathepsin-L like proteases, templates for homology modelling must be taken from
complexes and not from monomeric structures.
7.3 Model accuracy could be estimated sensibly by measur-
ing similarity to experimental structures
After comparing different experimental structures to each other, it was concluded that 0.38Å can
be used as a rough estimate for the RMSD below which the relationship between similarity
to an experimental structure, and similarity to a native protein structure, breaks down. Above
this value, comparison of models to experimental structures is a good method of estimating
accuracy. Below this value, the models are so close to the native structure that the errors in
experimental structures are of the same magnitude as the errors in the models. Of course
this value is only a very rough estimate and the actual number might be higher or lower and
vary from protein to protein. The best models constructed in the test set had RMSD values
of around 0.7Å and these were exceptional models where both protease and inhibitor were
modelled at very high sequence similarity. Most models are significantly less accurate than
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this and thus the small difference between the actual native structure and the experimental
structures are not a real factor in the measurement of the model accuracy.
7.4 There was no significant difference between the accu-
racy of hybrid and simple models
By comparing hybrid and simple models, from a subset of the test models, directly, it was
shown that they are of equal quality. This was done by selecting a subset of test models
so that the hybrid and simple models in the subset had the same distribution of sequence
similarity. Each of the major evaluation metrics were then compared between the hybrid
and simple models using the Mann-Whitney U-test. The result showed that the differences
between the two classes could be explained by random chance. Additionally, histograms
of the evaluation metrics showed similar distributions for the two groups. The differences
between the means of the two groups were also very small when compared to the values that
were being measured.
Since hybrid templates and simple templates produce models of the same quality, templates
for the individual components of the complexes (proteases and inhibitors) can be selected
independently from separate experimental structures. This means that, in most cases, tem-
plates with higher sequence similarity can be used. Further evidence that hybrid templates
are useful in building more accurate models is the fact that, for each of the nine targets in the
test set, the best model was based on a hybrid template in all nine cases. This proves that,
even if there were a slight cost to using hybrid templates, the benefit of using templates with
higher sequence similarity more than makes up for that cost.
7.5 Scoring functions provide useful information in certain
circumstances
It was found that both scoring functions examined, Rosetta energy and DOPE Z-score, was
able to identify the more accurate modelgroups. Both functions showed positive correlation
with RMSD, with DOPE Z-score showing slightly better performance. If there is uncertainty
about which template to use for a particular target, two or more potential templates can be
used to generate a few models each. Those models can then be evaluated with the scoring
functions to indicate which models are likely to be more accurate. The template that produces
the lowest scoring models can then be used further.
When it comes to selecting the best models out of a modelgroup, both functions generally
fail. This conclusion applies only to the specific method followed in this project. With other
modelling protocols the result might be different. However, the protocol followed here is
relatively common and there is reason to think that the result applies more widely than just
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for cysteine protease complexes. In the case of the self models, both functions were able to
make better-than-random selections of accurate models. What difference between the self
models and other models allows this is unclear. The only obvious difference is that the self
models are all highly accurate, with RMSD under 0.5Å. There were not enough models of the
hybrid and simple class in this accuracy range to get a sensible indication of the performance
of the scoring functions.
After energy minimization with the Rosetta 3.1 relax protocol, the ability of DOPE Z-score
to detect the more accurate models in a modelgroup increased very slightly across the entire
range of accuracy, although the correlation is still barely better than random.
7.6 Rosetta energy minimization improves the accuracy of
some models
For most of the very accurate models the energy minimization led to a decrease in accuracy
in terms of all evaluation metrics except fraction of native contacts. For less accurate models
a fraction of them were improved by the minimization procedure. The fraction of models
that were improved increases for less accurate models. One very interesting observation
was that the number of residue-residue contacts as defined for F-nat and F-non-nat increased
significantly for almost all models. This means that the energy minimization leads to tighter
packing of the interface residues and brings the two proteins closer to each other.
While there were improvements to many models, the practical use of the energy minimization
step is limited as the scoring functions are not able to identify the models that were improved.
If it was possible to identify the improved models, the utility of the minimization procedure
would be greatly improved.
7.7 Models for novel complexes were built and made avail-
able in a website
Models for a hundred and ten complexes were built using the same modelling protocol as for
the test set. They were evaluated using the same scoring functions and subjected to energy
minimization just like the test set models. Considering the sequence similarity between the
templates and the targets, the models are likely to be of high quality. The exception to this
statement is the models involving falstatin. The sequence similarity between falstatin and
chagasin was quite low and showed large insert, one of them very close to the interface.
Given this, it is unlikely that the falstatin models are very accurate although the relatively
low energies for some of the falstatin models do suggest that the sequence fits the structure
well.
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All the models of both sets as well as their scoring function results and evaluation metrics
in the case of the test models were made available online at http://rubi.ru.ac.za/cpmdb. This
was done so that other researchers can further analyze the data or use the models in studies.
7.8 Closing
The ultimate aim of the project was to model a large number of novel cysteine protease
complexes with very exact estimates of their accuracy. In this regard, the project fell short.
However, many important new insights were drawn from the investigations undertaken. The
most significant finding was that the hybrid templates produce models of similar quality to
the simple templates. How extensible this is to other protein complexes remains to be seen.
A lot of the software developed in the project is also re-usable for future research involving
protein structures and especially research involving high-throughput modelling.
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